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 Ubiquitylation is a cellular regulatory system found in all eukaryotic cells, which has 
managed to find a role in most pathways imaginable. The system works fundamentally through 
the ligation of a small protein known as ubiquitin onto a substrate. Depending on the context of 
the ubiquitin ligation, the substrate can be directed towards a number of cellular fates, the best-
studied being degradation of the substrate. While originally thought of as a signal for cellular 
disposal units to degrade aberrant proteins, we now know that ubiquitin plays a highly nuanced 
role in cellular epistasis, controlling everything from the cell cycle to the immune response. 
 Of the many enzymes involved in transferring ubiquitin molecules to and from targeted 
substrates, the cullin-RING ubiquitin ligases (CRLs) stand out for their particular breadth. 
Hundreds of CRLs exist in human cells owing to their modular structure, which in turn allows 
them to regulate an even greater number of substrates. They have also been targets of a number 
of different drug therapies, due to their involvement in the cell cycle and cancer. However, there 
are many vital gaps in how they function.  
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Particularly, CRLs function with a number ubiquitylating enzymes, referred to here as 
CRL partners. The first discovered of these, Cdc34, has been prominently studied for decades, 
but particular aspects of its molecular mechanism for transferring ubiquitin to substrates were not 
yet known. Further complexity was added when other CRL partners were discovered to also 
function in addition to Cdc34. Promising models suggested that these CRL partners could 
complement the activity of Cdc34 to maximize CRL turnover of substrate, but relatively little 
work had been done to study this system under the consideration of physiological conditions and 
concentrations. 
Therefore, the central aims of the studies within the planned dissertation are three-fold. 
First, by designing and refining current assays to set a guideline by which to measure complex, 
multi-component reactions. Second, by uncovering the molecular mechanism of Cdc34’s 
catalytic activity, so that it can be understood in the context of full CRL activity. Lastly, by 
determining how CRLs and their partners operate in the context of a living cell. For these efforts, 
we discovered a new molecular mechanism of Cdc34 activity, a new understanding of how CRL 
partners are balanced and used in the context of physiological CRL ubiquitylation pathways, and 
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1.1 The early history of the ubiquitin system 
The ubiquitin-proteasome system (UPS) was first discovered in 1977 as an unknown 
factor involved in the degradation of defective globin proteins from rabbit reticulocytes, though 
the ubiquitin protein itself was first identified as a factor in lymphocyte differentiation (Etlinger 
& Goldberg; Goldstein et al., 1975). Previous to that study, lysosomes were believed to be 
responsible for degradation of proteins, yet this new system could be recapitulated in cell-free 
lysates, and degraded proteins in an ATP-dependent manner. The following year ubiquitin was 
purified, described as a heat-resistant 9 kDa protein that was one of at least two factors required 
for this proteolytic system to function (Ciechanover, Hod, & Hershko, 1978). Ubiquitin’s degree 
of heat resistance allowed it to be purified to near-homogeneity at a time when recombinant 
expression of proteins was only nascent, which enabled rapid biochemical progress on the 
system as a whole. 
In 1980 it was discovered that the direct ligation of ubiquitin to proteins was responsible 
for their degradation, and that substrates could be modified by ubiquitin to various degrees 
(Ciechanover, Heller, Elias, Haas, & Hershko, 1980). Following this was the discovery of the 
ATP-dependent enzyme referred to as E1, possessing an ability to form a high-energy thioester 
bond with ubiquitin (Ciechanover, Heller, Katz-Etzion, & Hershko, 1981). A positive correlation 
between the degree of ubiquitylation and the rate of proteolysis became increasingly favored, 




By the early 80s, the complete, fundamental mechanism of ubiquitylation was uncovered, 
describing how a cascade of three enzymes transfers ubiquitin to a target substrate: the E1, E2, 
and E3 enzymes (Hershko, Heller, Elias, & Ciechanover, 1983). This was accomplished by 
utilizing additional affinity purification steps compared to previous papers, including E3 
purification via immobilized ubiquitin, as well as radiolabeled 125I-ubiquitin (Hershko et al., 
1983). What was discovered was that E2, ubiquitin-conjugating enzyme, was capable of 
accepting the ATP-dependent E1-ubiquitin thioester as an intermediate enzyme. Following the 
formation of E2-ubiquitin, purified E3 ubiquitin ligase could be added to the mixture, resulting in 




Figure 1.1 The basic ubiquitylation reaction cascade. E1 activates ubiquitin in an ATP-dependent 
manner, which hydrolyzes ATP and transfers a ubiquitin thioester to E2. E2-ubiquitin then 






Because both target substrates and ubiquitin alike were known to possess multiple 
lysines, it was initially unclear if the ubiquitylation system built chains of ubiquitin moieties in 
tandem, or if targets were simply modified at several lysines once. A preliminary study into the 
modes of ubiquitin modification found that reductive methylation of ubiquitin’s free amine 
groups would prevent the formation of more-modified substrates (Hershko & Heller, 1985). 
Additionally, they discovered that chains of linked ubiquitin, referred to as polyubiquitin, 
appeared to accelerate the process of degradation. 
It was well-established towards the end of the 80s that there existed more than a single E2 
or E3 involved in the UPS. For example, a study on the modification of histones uncovered three 
different E2s, named according to their molecular weights: E2-14K, E2-20K, and E2-35K 
(Pickart & Vella, 1988). Importantly, this study showed that the three E2s demonstrated variable 
activities, with the 35 kDa E2 being particularly well-suited towards building polyubiquitin 
chains, and the other two preferring mono-ubiquitylation of multiple substrate lysines. E2-20K 
was also the first ubiquitin-conjugating enzyme to be subjected to Edman sequencing, which 
would precipitate future studies on the similarities and differences between different E2s 
(Jentsch, McGrath, & Varshavsky, 1987). This included E2-35K, discovered to be the 
previously-described cell division cycle protein Cdc34 (Dutcher & Hartwell, 1982; Goebl et al., 
1988). 
Alongside the development of a mechanism for ubiquitylation existed studies specifically 
into the proteolytic component of the UPS. In 1983 components of the 26S proteasome were first 
identified as part of a large, multi-subunit complex (Wilk & Orlowski). By the end of the decade, 
further purification efforts had determined the presence of a catalytic core responsible for the 
breakdown of substrates, as well as the presence of other regulatory subunits (Eytan, Ganoth, 
4 
 
Armon, & Hershko, 1989; Hough, Pratt, & Rechsteiner, 1987). Ubiquitin chains linked via their 
lysine-48 residues were revealed to be preferred substrates for proteolysis, showing a particular 
role for linkage-specificity (Chau et al., 1989). It was later discovered that the 26S proteasome 
possesses a domain that preferentially binds to lysine-48 chains of four or more consecutive 
ubiquitins, which is considered to be the canonical signal for UPS-mediated degradation 
(Deveraux, Ustrell, Pickart, & Rechsteiner, 1994).  
Altogether, the study of the UPS had expanded from an unknown protein moiety and 
proteolytic factor, into a substantial network that regulated the stabilities of a vast number of 
proteins by the 1990s. Many great discoveries were made in years to come, involving hundreds 
of new ubiquitin ligases identified, and non-proteolytic functions for non-lysine-48 ubiquitin 
linkages, including cellular localization and DNA repair, expanding the role of ubiquitin in cell 
physiology to one often compared to that of phosphorylation (Spence, Sadis, Haas, & Finley, 
1995). The focus of this dissertation, however, is on a particular class of proteolysis-directed E3s 
known as the cullin-RING ubiquitin ligases. 
1.2 Background of Cullin-RING ubiquitin ligases (CRLs) 
CRLs comprise the largest family of E3 enzymes, and are able to modify and regulate 
hundreds of substrates (Sarikas Hartmann, & Pan, 2011). Many such substrates are known 
oncogenes, and the CRLs are often targeted by novel drug approaches towards the treatment of 
cancer (Gorelik et al, 2016; Soucy et al., 2009). Additionally, over two dozen viruses have been 
identified that directly target CRL components for the purpose of hijacking the UPS against the 
host cell, disrupting various immune responses and steps in the cell cycle (Mahon, Krogan, 
Craik, & Pick, 2014). Today, therapeutic research also hijacks E3s through drugs which target 
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novel substrates for degradation, a mechanism of drug design which was initiated using a CRL as 
a model (Pettersson & Crews, 2019; Sakamoto et al., 2001). 
The fundamental mode of activity of this important E3 family involves conserved 
structural elements shared between several family members. CRLs firstly possess a central 
protein called the cullin, identified independently in both C. elegans and S. cerevisiae in 1996 
(Kipreos, Lander, Wing, He, & Hedgecock; Mathias et al; Sarikas et al., 2011). Much about its 
mechanism was gleaned from crystallography work, revealing a long, relatively rigid protein 
which engaged multiple factors simultaneously (Zheng, Quansheng, Wang, & Wei, 2002). There 
are several cullins in humans: Cul1, Cul2, Cul3, Cul4a, Cul4b, Cul5, and Cul7, each of which 
possesses important binding regions at their N- and C-termini, serving as a scaffold between 
incoming substrates and incoming E2s. Additionally, Cul9/PARC and Apc2 of the anaphase-
promoting complex are related to the cullins, and mediate genome stability and the cell cycle, 








Figure 1.2 Generic structure of most CRLs. The CRLs possess a long, stable cullin protein, 
which bridges highly-modular substrate binding at the N-terminus with ubiquitylation machinery 
at the C-terminus. 
 
 
The cullins engage adaptor proteins at their N-termini, which in turn bind what is referred 
to as the substrate receptor. For Cul1, this adaptor protein is Skp1, which confers a high degree 
of modularity by being able to interact with a large number of substrate receptors (Feldman, 
Correll, Kaplan, & Deshaies, 1997; Skowyra, Craig, Tyers, Elledge, & Harper, 1997). Cul3 is an 
exception in that its adaptor protein also directly binds substrate, but it retains modularity typical 
of the cullins (Xu et al., 2003). The substrate receptor is the component of the CRL that directly 
interfaces an incoming substrate, allowing it to be in close proximity to the ubiquitylating 
components of the CRL. The cullins interact with a larger number of substrate receptors, the 
better-characterized including the F-box family for Cul1, the BTB family for Cul3, and the 
DCAF family for Cul4, each of which is known to possess at least 60 members (Sarikas et al., 
2011). The combined complex of Skp1-Cul1-F-box is referred to as the SCF complex. 
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Nearly 70 F-box proteins have been identified in humans, and among just those, 
individual receptors are known to function with multiple substrates. For example, Fbw7 
recognizes and degrades phosphorylated forms of several substrates including cyclin E, c-Myc, 
and c-Jun. Because of Fbw7’s wide role in degrading many oncogenes, dysfunction in its activity 
is often associated with cancer (Zheng et al., 2016). Collectively, the CRLs have the ability to 
regulate at least hundreds of substrates. 
The C-termini of cullins associate with a RING domain, which is the largest known 
family of E2-binding domains. The identity of the RING domain also varies depending upon the 
CRL family. For example, Cul1 is known to primarily utilize the RING-possessing Rbx1 protein, 
whereas Cul5 is known to bind Rbx2 instead (Kamura et al., 2004). Variability within both the 
RING domain itself as well as nearby residues within the cullin C-terminus are known to affect 
E2 binding, and therefore also the overall activity of a given CRL (Scott et al., 2014). 
The best-characterized E2 in a CRL context is Cdc34. Although first discovered and 
characterized through the 80s, it wasn’t until the discovery of the CRLs that a corresponding E3 
for Cdc34 was found (Pickart et al., 1988; Feldman et al., 1997; Skowyra et al., 1997). From 
there, the discovery of Rbx1 as the bridge between SCF and Cdc34 not only expanded the 
mechanism of SCF activity, but opened up the entire super-family of RING-containing proteins 
as potential E3 ubiquitin ligases (Kamura et al., 1999; Skowyra et al., 1999). To this day, Cdc34 
isn’t known to function with any E3s outside of the SCF family.  
The most critical features that distinguish Cdc34 among E2s include two negatively-
charged domains. First is the acidic tail, a long C-terminal stretch of residues that bind 
complementarily to a “basic canyon” of Cul1 (Kleiger, Saha, Lewis, Kuhlman, & Deshaies, 
2009). This enables Cdc34 to rapidly engage and disengage SCF at a rate faster than the ordinary 
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diffusion limit, allowing quick assembly of poly-ubiquitin chains onto an SCF-bound substrate 
(Kleiger et al., 2009). The second major feature is the acidic loop, a short, evolutionarily-
conserved insertion near the Cdc34 active site, which is critical for the enzyme’s activity and 
believed to be responsible for its excellent lysine-48 specificity (Petroski & Deshaies, 2005). 
Later studies expanded the repertoire of enzymes that interact with CRLs. UbcH5 is 
arguably the best-studied E2, referred to as a “promiscuous E2” due to its ability to engage a 
wide range of E3s (Brzovic & Klevit, 2006). Unlike Cdc34, UbcH5 tends to show minimal 
ubiquitin lysine specificity, and does not build poly-ubiquitin chains as rapidly. However, one 
model was proposed for SCF which argued that UbcH5 may function well as a substrate primer 
by transferring the first ubiquitin to specific substrate lysine residues, after which Cdc34 can 
rapidly extend lysine-48 chains (Wu, Kovacev, & Pan, 2010). 
The complexity of the CRL system was substantially expanded with the discovery that an 
E3, Arih1, can perform the same proposed role as UbcH5 but with a much broader set of F-boxes 
(Scott et al., 2016). Arih1 does not belong to the RING superfamily of E3s like the CRLs, but 
instead possesses a ‘RING-between-RING’ domain containing a catalytic cysteine, allowing it to 
perform similar to an E2 in directly transferring ubiquitin molecules to substrates. The increasing 
breadth of CRLs has accordingly raised many new questions. 
1.3 Research objectives 
Over twenty years of study towards the CRL family have greatly expanded knowledge 
not only of those enzymes but of the broader UPS. However, there are still substantial gaps in 
our understanding of Cdc34-CRL activity. A precise molecular mechanism by which Cdc34 
assembles lysine-48 ubiquitin chains was unknown until this study, which has implications 
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towards CRL activity on the whole. Additionally, the balance between the contributions of 
Cdc34, UbcH5, and Arih1 towards the CRL proteome were unclear. While optimally these CRL 
partners complement each other towards maximum modification of incoming CRL substrates, all 
of them must compete upon a single RING domain. Potential for complementation must also 
consider potential for redundancy and competitive inhibition. Furthermore, it remained possible 
that other unidentified CRL partners also existed. 
Therefore, the central aims of the studies within are to further explain mechanisms of 
CRL activity, from the molecular level up to the cellular level. Creating a more detailed model of 
how CRL partners function with CRLs will help to also contribute to medical treatments 
targeting these proteins. Within, we provide novel methods of assaying ubiquitylation activity, 
uncover a new detailed mechanism of Cdc34 activity, new understanding of how CRL partners 
are balanced and used in the context of CRL ubiquitylation pathways, and identify a new partner 
of SCF with activity complementary to Cdc34. 
1.3.1 Aim 1, preliminary design of ubiquitylation assays and validation of enzyme activity 
Cdc34 was among the earliest of E2 enzymes discovered, and among the first to be 
attributed a specific role in cell physiology (Dutcher & Hartwell, 1982; Goebl et al., 1988). In the 
decades to follow Cdc34 has been recombinantly expressed and purified for use in various in 
vitro reconstitution assays, but outside of a brief comment by Pickart et al., that “solutions of E2-
35K… were quite labile to freezing and thawing”, there has been little discussion regarding its 
relative stability (1988, p. 15078). For the purpose of establishing more advanced assays 
comparing the activities of different E2s, it is necessary to know ideal storage and reaction 
conditions at which to use the enzymes. This study makes up the content of Chapter 2. 
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Method 1a: Purify Cdc34 and UbcH5c to homogeneity and store under various conditions. 
Method 1b:  Identify the sensitivity and ideal conditions for keeping Cdc34 and UbcH5c under 
long-term storage through common ubiquitylation assays. 
1.3.2 Aim 2, discovering the mechanism of Cdc34 lysine-48 specificity  
Cdc34 remains a heavily studied E2, and many of its defining characteristics, such as its 
mode of binding to thioesterified donor ubiquitin or to the Cul1 basic canyon, had been 
determined to atomic-level resolution. It has also been viewed as a promising target for drug 
design due to its role in CRL activity, and the first drug inhibitor of an E2 was targeted to Cdc34 
(Ceccarelli et al., 2011). Despite this, the critical nature of how Cdc34 specifically orients a 
substrate-conjugated acceptor ubiquitin to build lysine-48 chains with 99% purity was largely 
unknown, though some light had been shed in terms of approximate models (Chong et al., 2014; 
Petroski & Deshaies, 2005). Therefore, knowing this fundamental aspect of Cdc34’s mechanism 
will provide new insights into lysine-48 ubiquitin chemistry, the greater range of CRL activity, 
and potential new avenues for drug design and treatment. This study makes up the content of 
Chapter 3. 
Method 2a: Generate a litany of theoretical models showing potential Cdc34-ubiquitin structures. 
Method 2b: Generate various mutant Cdc34 and ubiquitin constructs and uncover double-mutant 
cycle using preliminary E3-independent di-ubiquitin assay. 




1.3.3 Aim 3, building a model to more accurately detail the interplay between CRLs and their 
cognate E2s 
The CRL family constitutes the largest known family of E3 ligases. While initially 
believed to function with only the E2 Cdc34 in human cells as is the case in S. cerevisiae, studies 
have revealed that CRLs may function with multiple ubiquitylating enzymes, including both E2s 
as well as other E3s (Scott et al., 2016; Wu et al., 2010). The precise balance between these CRL 
partner enzymes is unclear, however. Because substantial effort has been put into the study of 
CRLs on the whole, as well as their regulation and therapeutic potential, particularly on the 
substrate side of CRLs, we seek to uncover how it is that these E3s operate with their cognate 
E2s, under conditions as accurate to physiological as possible. This study makes up the content 
of Chapter 4. 
Method 3a: Measure fundamental kinetic parameters of CRL partners for SCF to discover their 
maximum potential activities. 
Method 3b: Employ single reaction monitoring and fluorescence microscopy to determine the 
cellular concentrations and localization of these CRL partners. 
Method 3c: Repeat kinetics work using CRL partner concentrations guided by cellular 
physiology, in order to more accurately model SCF ubiquitylation and the relative contributions 
of each CRL partner. 
Method 3d: Test the model through siRNA and CRISPR experiments, Western blotting for 
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USING IN VITRO UBIQUITYLATION ASSAYS TO ESTIMATE THE                          
AFFINITIES OF UBIQUITIN-CONJUGATING ENZYMES                                                  
FOR THEIR UBIQUITIN LIGASE PARTNERS1 
2.1 Abstract 
 Ubiquitin ligases (E3s) function by binding to both a protein substrate and to ubiquitin-
conjugating enzymes (E2s) bound to ubiquitin. E3s facilitate the transfer of ubiquitin from the 
E2 active site to an E3-bound substrate. Thus, the affinity of the interaction of an E2 with its E3 
partner is of considerable interest. The purpose of this work is to: (1) provide protocols for the 
purification of the human E2 Cdc34, as well as for some additional protein components needed 
for the assays described here whose purification protocols haven’t been described elsewhere in 
detail; (2) provide the researcher with critical information regarding the proper long-term storage 
of these enzymes to retain maximal activity; (3) provide a protocol to benchmark Cdc34 activity 
with previously described activity levels in the literature; and (4) provide a simple and rapid 
means of measuring E2 affinity for an E3.  
 
                                                          
1 This chapter was adapted from a published work: 
Hill S., Hill C., Kleiger, G. (2018). Using In Vitro Ubiquitylation Assays to Estimate the 
Affinities of Ubiquitin-Conjugating Enzymes for Their Ubiquitin Ligase Partners. Methods in 





 Protein ubiquitylation involves the coordinated action of 3 classes of enzymes: ubiquitin-
activating enzyme (E1), ubiquitin-conjugating enzyme (E2), and ubiquitin ligase (E3). Ubiquitin 
is first activated by the E1, forming a covalent complex between E1 and the C-terminus of 
ubiquitin. The E2 then binds to the E1–ubiquitin complex, and ubiquitin is transferred from E1 to 
the E2 active site. E3s act as scaffolds, binding both to the protein substrate as well as to the E2–
ubiquitin complex (Yau & Rape, 2016). In most cases, E3s also stimulate the transfer of 
ubiquitin from the E2 onto a lysine residue on either the E3-bound substrate or on substrate-
modified ubiquitins (Zheng & Shabek, 2017). Multiple lysine residues may become modified 
with ubiquitins prior to substrate dissociation from the E3 (termed multi-mono ubiquitylation). In 
other cases, ubiquitins can be transferred from E2 to ubiquitins on the substrate forming a chain 
(termed poly-ubiquitylation). In either case, the ubiquitylated protein is typically degraded by the 
26S proteasome (Swatek & Komander, 2016). 
 Since E2 interaction with E3 is required for substrate ubiquitylation, it is often an 
advantage for the researcher to know the affinity of an E2 for its cognate E3. For instance, 
having an estimate of the affinity (e.g. equilibrium dissociation constant for E2 binding to E3) is 
useful when designing in vitro ubiquitylation assays. The affinity informs the researcher of the 
minimal concentration of E2 that is necessary to fully saturate the E3. Knowing the affinity of E2 
for E3 is also relevant since proteomic methods are now available to estimate the concentrations 
of proteins inside the cell (Mirzaei, 2010). Comparison of cellular E2 and E3 concentrations with 
their affinity for each other provides insight into whether E3 activity is maximal within the cell. 
Lastly, both E2s and E3s have been found to contain mutations in humans that may lead to 
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disease, and the ability to measure E2 affinity for E3 will enable the determination of whether 
these mutations disrupt the E2–E3 complex.  
 A variety of biophysical methods have been adapted for measuring the equilibrium 
dissociation constant of an E2 for an E3, including surface plasmon resonance, isothermal 
calorimetry, and fluorescence resonance energy transfer (FRET) as well as fluorescence 
polarization (Buetow et al, 2015; Das et al, 2013; Eletr, Huang, Duda, Schulman, & Kuhlman, 
2005; Eletr & Kuhlman, 2007; Kleiger et al, 2009; Wright, Mace, & Day, 2016). However, the 
development of these assays is nearly always expensive and time consuming. It is also common 
that these methodologies will not adapt to specific pairs of E2s and E3s, meaning that the 
researcher will have to scout through several before successfully developing the binding assay. 
Finally, most of these methods require substantial technical and theoretical know-how in order to 
employ them. Thus, it would be desirable to have a method that is conceptually simple, easy to 
use, and inexpensive to implement. 
 E2 affinity for E3 has also been estimated by measuring the Michaelis-Menten kinetics of 
ubiquitylation reactions containing increasing amounts of E2 and then using the reaction 
velocities to estimate the Michaelis constant, Km, of E2 for E3. Previous studies have shown that 
the KM is often consistent with estimates of the affinity of an E2 for E3 derived from traditional 
biophysical methods (Kleiger, 2009). Measuring the Michaelis-Menten kinetics is particularly 
powerful because all one needs to perform the experiments are highly purified proteins and a 
substrate that can be detected quantitatively. Here we describe the purification of the human E2 
Cdc34 (also referred to as Ube2R1/2) as well its physiological E3 partner Skp1-Cullin Fbox 
ubiquitin ligase (SCF). The purification of a synthetic peptide derived from the bona fide SCF 
substrate β-catenin modified with a single ubiquitin is also described. All of these proteins retain 
19 
 
their activities during long-term storage. However, it is critical to follow specific procedures 
during storage, and attention is drawn to these points within the protocols. An assay is described 
to facilitate comparison of the activities of the freshly prepared enzymes with benchmark levels 
from the literature. Finally, the procedure for measuring the KM of Cdc34 or another human E2, 
UbcH5, for SCF is described, and several important considerations regarding both the 
implementation as well as the analysis are noted. 
2.3 Materials 
Prepare all solutions using ultrapure water (prepared by purifying deionized water, to attain a 
sensitivity of 18 MΩ-cm at 25 °C) and analytical grade reagents. 
2.3.1 Buffers and solutions 
1. Luria broth (LB): 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract 
2. 100 mg/mL ampicillin stock 
3. 34 mg/mL chloramphenicol stock (in ethanol) 
4. 0.8 M isopropyl β-D-1-thiogalactopyranoside (IPTG) stock 
5. 1x phosphate buffered saline with Tween 20 (PBS-T): 12 mM phosphate pH 7.4, 137 mM 
NaCl, 2.7 mM KCl, 0.1% (v/v) Tween 20 
6. Lysis buffer: 30 mM Tris-HCl pH 7.5, 250 mM NaCl, 20 mM imidazole-HCl pH 8.0, 0.1% 
IgePal, 5% glycerol, 1 mM β-mercaptoetanol, commercial protease inhibitor cocktail lacking 
EDTA (PIC) (see Note 1) 
7. Wash buffer: 30 mM Tris-HCl pH 7.5, 250 mM NaCl, 20 mM imidazole-HCl pH 8.0, 5% 
glycerol, 1 mM β-mercaptoethanol 
8. Tobacco etch virus protease (TEV) buffer: 50 mM Tris-HCl pH 8.0, 50 mM NaCl, 5% 
glycerol, 1 mM DTT, 0.5 mM EDTA 
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9. Nickel elution buffer: 50 mM HEPES-Na, pH 7.5, 250 mM NaCl, 300 mM imidazole-HCl 
10. 0.5 M imidazole-HCl pH 8.0 
11. Coomassie blue solution: 40% (v/v) methanol, 10% glacial acetic acid (v/v), 0.1% 
Coomassie Brilliant Blue R-250 (w/v) 
12. Storage buffer: 30 mM Tris-HCl pH 7.5, 100 mM NaCl, 10% glycerol, 1 mM DTT 
13. Ion exchange buffer A: 25 mM HEPES-Na pH 6.8, 5% glycerol, 1 mM β-mercaptoethanol 
14. Ion exchange buffer B: 25 mM HEPES-Na pH 6.8, 500 mM NaCl, 5% glycerol, 1 mM β-
mercaptoethanol 
15. 10x neddylation buffer: 300 mM Tris-HCl pH 7.5, 50 mM MgCl2, 20 mM ATP 
16. 1 M dithiothreitol (DTT) 
17. 10x reaction buffer: 300 mM Tris-HCl pH 7.5, 1 M NaCl, 50 mM MgCl2, 20 mM DTT, 20 
mM ATP 
18. 2x reducing quench buffer: 100 mM Tris-HCl pH 6.8, 30 mM EDTA, 20% (v/v) glycerol, 
2% (w/v) SDS, 4% (v/v) β-mercaptoethanol, 0.1% (w/v) bromophenol blue 
2.3.2 Reagents 
All proteins and enzymes described are of human origin unless otherwise stated. 
1. 1.5 mL Eppendorf tubes 
2. Rosetta BL21(DE3) chemically competent cells 
3. 10 cm LB-agar plates: 10 g/L tryptone, 10 g/L NaCl, 5 g/L yeast extract, 15 g/L agar 
4. 15 and 50 mL conical tubes 
5. Ni-NTA agarose resin 
6. Disposable 25 mL columns 
7. Commercial TEV protease (must possess His6 tag) 
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8. Protein molecular weight marker 
9. Disposable desalting columns (see Note 2) 
10. 3 and 10 kDa cut-off centrifugal concentrators 
11. 0.22 μm spin filters 
12. Liquid nitrogen 
13. Commercial His6-Nedd8 
14. APPBP1/UBA3, bacterially expressed as a GST fusion (Huang & Schulman, 2005) 
15. Ubc12, bacterially expressed as a GST fusion (Chiba, 2005) 
16. Commercial His6-ubiquitin 
17. Ube1 (E1), expressed in insect cells as a GST fusion or in bacterial cells with a His6 affinity 
tag as described (Beaudenon, 2005; Zheng, 2010) 
18. UbcH5, bacterially expressed as a GST fusion (Lorick, Jensen, & Weissman, 2005) 
19. Cul1Lys 720 Arg-Rbx1 complex (C/RK720R), using the Split-n-Coexpress method (Li, Pavletich, 
Schulman, & Zheng, 2005)(see Note 3) 
20. Skp1/βTRCP complex, expressed in insect cells as described (Li, 2005) 
21. Commercial β-catenin substrate peptide (β-cat) (see Note 4)(Saha, 2008) 
22. γ-32P ATP 
23. Commercial protein kinase A (PKA) enzyme 
24. Commercial ubiquitin protein 
25. Lys 48 Arg (K48R) ubiquitin with N-terminal PKA phosphorylation site (see Note 5) 
26. Ubiquitin containing C-terminal aspartic acid residue (D77 ubiquitin) (see Note 5); 
preparation described in section 3.1 
27. Cdc34, bacterially expressed; preparation described in section 3.2 
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28. Cul1-Rbx1 complex (C/R), using the Split-n-Coexpress method (see Note 6) 
29. Cul1-Rbx1-Nedd8 (C/RNedd8); preparation described in section 3.3 
30. Mono-ubiquitin β-catenin substrate (β-cat-(Ub)1); preparation described in section 3.4(Saha, 
2008) 
31. SDS-PAGE gels, 18% acrylamide 
32. 3 mm chromatography paper 
33. Ultra clear cellophane (see Note 7) 
2.3.3 Equipment 
1. Refrigerated protein purification workstation including: 
a. Gradient pump with UV detector 
b. Size-exclusion chromatography column optimized for resolving proteins between 3 
kDa and 75 kDa 
c. Cation-exchange column 
d. Fraction collector 
2. UV/vis spectrophotometer 
3. Tabletop centrifuge 
a. Rotor compatible with 1.5 mL Eppendorf tubes 
4. Large centrifuge 
a. Rotor capable of processing 50 mL volumes at 32000 g 
b. Rotor capable of processing 1 L volumes at 5000 g 
5. Gel dryer (see Note 8) 
6. Storage phosphor screen 




2.4.1 Expression and purification of human acceptor ubiquitin 
1. Clone the gene for human ubiquitin and containing an N-terminal His6 affinity tag and C-
terminal aspartic acid residue (D77 UB) into pET-11b or an equivalent bacterial protein 
expression vector. 
2. Transform 100 ng of plasmid into 50 μL of chemically competent Rosetta(DE3) cells, and 
recover after heat shock in 350 μL of LB for 1 hour with mild shaking at 37 °C. Deposit 150 
μL of the transformants onto a 10 cm agar plate containing 100 μg/mL ampicillin and 34 
μg/mL chloramphenicol, and let grow overnight. 
3. Wash the bacterial colonies from the plate with 6 mL of LB. Add this equally to 2 Fernbach 
flasks each containing 1 L of LB supplemented with 100 μg/mL ampicillin, 34 μg/mL 
chloramphenicol, and 10 g/L dextrose (see Note 9).  
4. Shake the cultures at 120 rpm at 37 °C until they reach an O.D. of 0.8, which should take 
approximately 4.5 hours.  
5. Pellet cultures at 5000 g for 10 minutes in 1 L centrifuge bottles, discard the old media, and 
transfer the cells to fresh LB supplemented with only 0.4 mM IPTG. 
6. Shake the cultures at 30 °C for 4 hours, pellet them at 5000 g for 10 minutes, and discard the 
media. 
7. Resuspend each pellet with 25 mL of 1x PBS-T, and then pellet each in a 50 mL conical at 
5000 g for 10 minutes. Discard supernatant, and then drop-freeze pellets in liquid nitrogen 
before long-term storage at -80 °C. 
8. Equilibrate a size exclusion column with a molecular weight range of 3 kDa to 75 kDa with 
at least 3 column volumes of ddH2O. Repeat with storage buffer. 
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9. Thaw cells on ice and add 25 mL of cold lysis buffer to each bacterial pellet. 
10. Sonicate each pellet three times for 90 seconds using 0.5 second pulses, with a 50% duty-
cycle. Keep lysates in an ice-water bath at all times. Provide at least 5 minutes for lysates to 
cool immediately after each round of sonication. After sonication each lysate should be 
approximately 30 mL. 
11. Equilibrate 0.5 mL of Ni-NTA agarose resin by first resuspending in 10 mL wash buffer 
followed by centrifugation at 1000 g for 2 minutes. Remove the supernatant and then repeat 
with another 10 mL of wash buffer. 
12. Transfer lysates to centrifuge tubes and spin at 32000 g for 60 minutes. Transfer each 30 mL 
of lysate to 0.5 mL of the Ni-NTA resin. Rotate the lysate-resin mixture for 1 hour at 4 °C. 
13. Centrifuge the lysate-resin mixture at 1000 g for 2 minutes. Discard the supernatant. Now 
wash the resin with 10 mL of wash buffer by resuspending the resin thoroughly. Repeat 3 
times before transferring the final resin-wash buffer mixture to a disposable 25 mL column 
where the filter has been pre-equilibrated in wash buffer. 
14. Wash the resin in the disposable column twice each time with 20 mL of wash buffer, waiting 
for the flow of buffer to stop completely before continuing. Apply a stop cock the column. 
15. Add 2.7 mL of nickel elution buffer to the resin and incubate 10 minutes. Elute into a 3 kDa 
cutoff centrifugal filter. 
16. Concentrate to a final volume to achieve the best resolution with your size exclusion column. 
We always pass the protein solution through a 0.22 μm centrifugal filter unit prior to loading 
onto the column. Check the fractions with a UV signal by SDS-PAGE and Coomassie blue 
solution to ascertain the final level of protein purity. 
25 
 
17. Collect all fractions containing pure D77 UB. Measure the absorbance of the solution at 280 
nm, using an extinction coefficient of 1280 M-1cm-1 to determine the initial protein 
concentration. Concentrate the sample using a 3 kDa cutoff concentrator to at least 500 μM, 
ideally 1 mM or higher (see Note 10). The typical final yield of purified D77 UB is 8 mg per 
1 L of starting culture.  
18. Aliquot protein and drop freeze in liquid nitrogen prior to long term storage at -80 °C. 
2.4.2 Expression and purification of human Cdc34 
1. Clone the gene for human Cdc34B/Ube2R2 (hereafter referred to as Cdc34), transform into 
chemically competent cells, and prepare bacterial cultures, as described in section 2.4.1, steps 
1 through 3.  
2. Shake the cultures at 120 rpm at 37 °C until they reach an OD of 1.0-1.2, which should take 
approximately 4.5 hours. 
3. Follow steps 5 through 7 in section 2.4.1. 
4. Follow steps 9 through 14 in section 2.4.1.  
5. Begin equilibrating a commercial desalting column into TEV buffer according to the 
manufacturer. 
6. Add 2.7 mL of nickel elution buffer to the Ni-NTA resin and incubate for 10 minutes.  
7. Collect the eluate and add an appropriate volume to the desalting column according to the 
manufacturer. Elute the protein from the desalting column using TEV buffer and collect in a 
15 mL conical tube. 
8. The protein should be pure enough to approximate the yield by measuring the absorbance at 
280 nm. Use an extinction coefficient of 37200 M-1cm-1. Add additional TEV buffer to bring 
the final volume of the eluate to 6 mL. 
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9. Collect a 20 μL sample prior to addition of TEV protease and dilute in 2x reducing quench 
buffer. Add 1 mg of TEV per 25 mg of protein in the eluate. Incubate at 4 °C overnight 
without rotating.  
10. Equilibrate a size exclusion column as described in step 8 section 2.4.1. 
11. The next morning, load a SDS-PAGE gel with protein molecular weight marker, 6 μL pre-
TEV sample from step 18, and 6 μL of post-TEV sample. Run the gel and stain in Coomassie 
blue solution. If TEV digestion of Cdc34 was efficient, a slight downwards shift of a 30 kDa 
band in the pre-TEV lane, corresponding to loss of the His6 tag, should be visible in the post-
TEV lane. Digestion need not be 100% efficient before proceeding to the next step (see Note 
11). 
12. Equilibrate another 0.5 mL of Ni-NTA resin in wash buffer as described in step 11 section 
2.4.1. Use a fresh desalting column to equilibrate Cdc34 into wash buffer and to remove the 
EDTA. Add the Cdc34 eluate to the Ni-NTA resin and rotate for one hour at 4 °C. Add the 
slurry to a 25 mL disposable column where the filter has been pre-equilibrated in wash 
buffer, this time collecting the flow-through. His6-TEV and Cdc34 still containing the His6 
tag will remain bound to the resin (see Note 11). 
13. Concentrate the protein using a centrifugal concentrator with a 10 kDa cutoff as necessary 
according to the maximum load volume of the size exclusion column. Filter the protein in a 
microcentrifuge using 0.22 μm spin filters immediately prior to loading onto the column. 
14. After separation, load 6 μL of all fractions corresponding to the strongest peak by UV-
absorbance on a SDS-PAGE gel. Stain the gel in Coomassie blue solution to verify the 
product and purity.  
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15. Combine all fractions containing Cdc34. Check the protein concentration by measuring the 
absorbance at 280 nm using an extinction coefficient of 37200 M-1cm-1. Concentrate the 
protein to 100 μM (see note 12). The typical final yield of purified Cdc34 is approximately 2 
mg per 1 L of culture.  
16. Aliquot the sample between as many tubes as possible (see Note 12), then drop freeze in 
liquid nitrogen prior to long term storage at -80 °C. Cdc34 can be safely stored for at least 3 
years this way. 
2.4.3 Neddylation of Cul1-Rbx1 and purification  
1. Our protocol is a modified version of that described previously (Saha, 2008).  
2. Equilibrate a cation exchange column with 5 column volumes of ion exchange buffer A, then 
5 column volumes of ion exchange buffer B, and then 5 column volumes of buffer A again. 
Reset the UV absorbance setting on your chromatography instrument. Equilibrate 0.5 mL of 
Ni-NTA resin in wash buffer as described in step 11 section 2.4.1. 
3. Add the following components in sequential order (values for the final concentrations of each 
are shown). While the volume of the reaction can vary, we recommend at minimum a 
reaction volume of 1 mL to recover a sufficient amount of product, and 2.5 mL is preferable 
if sufficient reagents are available.  
a. ddH2O 
b. 10x neddylation buffer 
c. 6 μM His6-Nedd8 
d. 1 μM APPBP1/UBA3. Incubate for 1 minute before proceeding to next step.  
e. 5 μM Ubc12, Incubate for 1 minute before proceeding to next step.  
f. 4 μM C/R 
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4. After addition of C/R, incubate reaction for 12 minutes at room temperature, then quench by 
adding 1 M DTT to achieve a final concentration of 10 mM. Aliquot 5 μL of the reaction into 
5 μL of 2x reducing quench buffer and keep for analysis of the reaction efficiency (see step 6 
below).  
5. Immediately load the full reaction onto the cation exchange column, and wash with buffer A 
at 0.3 mL/min until the UV signal is back to zero. Recover the flow-through in case the 
protein does not bind to the column. 
6. Initiate a salt gradient with ion exchange buffers A and B with a flow rate of 0.3 mL/min. We 
typically collect fraction volumes of 0.5 mL. C/RNedd8 should begin eluting from the column 
at a concentration of 150 mM NaCl (~30% buffer B). After separation is complete, load 6 μL 
of the fraction corresponding to the strongest peak on an SDS-PAGE gel, along with the 
sample from step 4 as well as the flow-through sample from step 5. Stain in Coomassie blue 
solution to verify product formation and purity. 
7. Collect all fractions containing C/RNedd8, and supplement with 0.5 M imidazole-HCl pH 8.0 
to a final concentration of 20 mM. Incubate the eluate on the Ni-NTA resin with rotating for 
1 hour at 4 °C. 
8. Pour eluate over a disposable column where the filter has been pre-equilibrated in wash 
buffer, discarding the flow-through. Wash the resin thoroughly with 10 mL wash buffer, 
waiting for the flow of buffer to stop completely before continuing. Repeat with another 10 
mL of wash buffer.  
9. Place a stop cock on the exit port of the column, and add 2.5 mL of nickel elution buffer. 
Incubate for 10 minutes. 
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10. Collect the eluate, and then exchange the protein into storage buffer by size exclusion 
chromatography, dialysis, or repeated cycles of reducing sample volume followed by dilution 
into storage buffer using a centrifugal concentrator (see Note 13). The extinction coefficient 
for C/RNedd8 is 115000 M-1cm-1. Concentrate to at least 4 μM for use in biochemical assays.  
11. Aliquot the protein into several microcentrifuge tubes, and then drop freeze into liquid 
nitrogen and store at -80 °C (see Note 14). Typical yield of purified C/RNedd8 is 
approximately 50% of starting C/R. 
2.4.4 Preparation and purification of mono-ubiquitin β-catenin substrate  
1. Our protocol is a modified version of that described previously (Saha, 2008).  
2. Add the following components in sequential order (values for the final concentrations of each 
are shown), with a total reaction volume of at least 1 mL to recover a sufficient amount of 
product.  
a. ddH2O 
b. 10x reaction buffer 
c. 130 μM His6-ubiquitin 
d. 125 nM human E1, incubate 1 min 
e. 2 μM human UbcH5, incubate 1 min 
f. 450 nM C/RK720R 
g. 450 nM Skp1/βTRCP 
h. 100 μM β-cat peptide 
3. Allow reaction to proceed overnight at approximately 22 °C (about 12 hours) and quench 
with the addition of 1 M DTT to a final concentration of 10 mM. 
30 
 
4. Filter the reaction contents using a 0.22 μm spin filter, then load onto a size exclusion 
column with a molecular weight range of 3 kDa to 75 kDa. β-cat-(Ub)1 should be the third-
to-last peak to elute, followed by a peak with weak UV absorbance corresponding to 
ubiquitin and a peak with large UV absorbance corresponding to unmodified β-cat. Load 
samples from these peaks onto a SDS-PAGE gel and stain with Coomassie blue solution to 
confirm the fractions containing the desired product and to assess purity. 
5. Equilibrate 0.5 mL of Ni-NTA resin in wash buffer as described in step 11 section 3.1. 
6. Follow steps 7 through 9 in section 3.3 (see Note 15).  
7. Collect the eluate and concentrate to a final volume that is appropriate for your size exclusion 
chromatography column, using a 3 kDa cutoff concentrator. Filter the sample using a 0.22 
μm spin filter, and load onto the column collecting 0.5 mL fractions during the entire run. 
8. Concentrate fractions containing the final product to 50 μM. The extinction coefficient used 
for β-cat-(Ub)1 is 9500 M-1cm-1. The typical yield of β-cat-(Ub)1 relative to starting substrate 
is 15%. Drop freeze aliquots in liquid nitrogen and store at -80 °C. 
2.4.5 Di-ubiquitin synthesis assay 
1. Thaw K48R ubiquitin, PKA kit reagents, and γ-32P ATP on ice. Follow the kit 
manufacturer’s instructions to prepare a 32P K48R ubiquitin stock of 100 μM. 32P K48R can 
go through at least 10 freeze-thaw cycles. 
2. Prepare a reaction mixture for a final volume of 20 μL with the sequential addition of 
ddH2O, 10x reaction buffer, and 32P-labeled K48R ubiquitin to a final concentration of 10 
μM. 
3. Prepare six 1.5 mL Eppendorf tubes, each containing 3 μL of 2x reducing quench buffer. 
31 
 
4. Add human E1 to a final concentration of 0.25 μM to the reaction mixture, lightly vortex, and 
incubate for 1 minute to achieve thioester formation between E1 and ubiquitin. 
5. Add human Cdc34 to a final concentration of 2 μM to the reaction mixture, lightly vortex, 
and incubate for 2 min. 
6. If measuring E3 activation, add C/RNedd8 to a final concentration of 0.1 μM. Lightly vortex, 
then briefly spin down contents using a tabletop microcentrifuge to ensure that the reaction 
contents are entirely contained in the bottom of the tube. 
7. Immediately add D77 ubiquitin to a final concentration of 100 μM to initiate the reaction. 
Lightly vortex, and begin collecting time points by transferring 3 μL of the reaction to the 
respective tubes containing quench buffer. If measuring E3 activation, time points every 10 
seconds are required. If measuring E3-independent activity, 2 minutes per time point should 
be sufficient to achieve adequate product formation for the quantitation step (see Notes 16 
and 17). 
8. Load the substrates and products from each time point onto a reducing SDS-PAGE gel. A 
reaction lacking human E1 typically serves as the negative control. 
9. Place your SDS-PAGE gel onto a filter paper that has already been soaked in ddH2O, then 
overlay a wet sheet of cellophane onto the gel. Thoroughly dry the gel, and then image using 
a phosphor screen, being careful not to overexpose (see Note 8). Visualize the gel using any 
molecular imager capable of detecting phosphorescence (Figures 2.1A, 2.1B). 
10. Using the software with your molecular imager, quantitate the amount of both unmodified 
substrate and di-ubiquitin per reaction time point. Use the area where product normally 
appears in the minus E3 negative control as a measure of background levels, using object 
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average subtraction. Subtract this from all substrate and product bands and record the 
intensities of each. 
11. Divide the amount of di-ubiquitin product by the total signal produced by both product and 
substrate per lane to calculate the percentage of substrate converted to product. Next, 
multiply the percentage by the starting concentration of K48R ubiquitin substrate (10 μM), 
and divide by the concentration of Cdc34 (2 μM) to find the normalized values. 
12. Using a graphing software package, input the normalized values for product into the Y-axis 
and time (hours) into the X-axis. Use linear regression to determine the best fit to the data. 
The slope of the line provides Cdc34 activity (kobs) in units of hour-1. Typical rates for both 
the E3-independent and E3-dependent assays are 2.3 hour-1 and 37 hour-1, respectively.  
13. Use the r2 value as a basis to determine quality of the fit. In our experience, a value of less 
than 0.98 indicates the possibility of excessive product formation for the later time points, or 






Figure 2.1 A simple Cdc34-dependent di-ubiquitin synthesis assay. (A) Autoradiogram of a time 
course for a reaction containing human Cdc34, K48R donor ubiquitin, and D77 acceptor 
ubiquitin. (B) Same as (A) but with the addition of C/RNedd8. Notice that the presence of C/RNedd8 
enhances the rate of di-ubiquitin formation by 16-fold. (C) Linear regression of product 
formation versus time for the E3-independent reaction in (A). Notice that product formation is 
highly linear with respect to time. (D) Linear regression of product formation versus time for the 
E3-dependent reaction in (B). 
 
 
2.4.6 Assay to estimate the affinity of Cdc34 and UbcH5 for SCF 
1. Thaw β-cat or β-cat-(Ub)1 substrate, PKA kit reagents, and γ-32P ATP on ice. Following the 
kit manufacturer’s instructions, prepare a 32P-labeled substrate stock of at least 50 μM (see 
Note 18). 
2. Thaw 10x reaction buffer, ubiquitin, E1, Cdc34, UbcH5, C/RNedd8, and Skp1/βTRCP 
complex on ice, then spin down all aliquots briefly using a microcentrifuge to pellet any 
precipitate that may have formed. 
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3. Prepare a 2-fold dilution series of Cdc34 and UbcH5 using storage buffer and extending to at 
least 9 samples. For wild-type Cdc34 and UbcH5, 100 μM stocks are a good starting point 
for the 2-fold dilution series such that the E2s will achieve saturation of SCF(βTRCP). If 
assaying mutant E2s that may compromise binding to E3, concentrate the E2 stocks above 
100 μM immediately prior to performing the experiment and do not freeze these samples for 
long-term storage (see Note 12). Since E2s are diluted in storage buffer, it is critical that each 
reaction contain the same volume of E2 over the entire dilution series (see Note 19). 
4. Prepare an Eppendorf tube containing equimolar amounts of C/RNedd8 and Skp1/βTRCP 
complex (together referred to as SCF(βTRCP). 
5. Prepare a stock of ddH2O, 10x reaction buffer, ubiquitin, and E1 in an Eppendorf tube. 
Prepare enough stock to be equally distributed to nine Eppendorf tubes for the E2 titration 
series. Add enough ubiquitin and E1 such that their final concentrations in each reaction will 
be 60 μM and 1.0 μM, respectively. We typically use a final reaction volume of 10 μL.  
6. Add the E2s from the dilution series sample to its respective reaction tube, vortexing briefly 
after each addition. We’ve done this assay by diluting the E2 samples either 1:10 or 1:5 into 
the reaction mixture. Allow the E2s to charge with ubiquitin for 2 minutes (slightly longer is 
acceptable if necessary to fully pipette all reactions). 
7. Add SCF(βTRCP) to a final concentration of 0.1 μM, vortexing briefly. Then briefly spin 
down reaction contents in microcentrifuge. Do not allow SCF(βTRCP) to incubate with the 
other components prior to initiating the reaction for more than 1 minute (see Note 20). 
8. Start a timer when adding radiolabeled substrate at a final concentration of 5 μM to the 
reactions, lightly vortexing each reaction after the addition of substrate. If you are working 
with Cdc34 and β-cat, an 8 minute reaction duration is sufficient to convert approximately 
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15% of substrate to product. If you are working with Cdc34 and β-cat-(Ub)1, or UbcH5 and 
β-cat, a 2.5 minute time point should be sufficient to also observe 15% substrate conversion 
to product. Quench each reaction in 2x reducing quench buffer at the desired time. 
9. Resolve substrates and products on an 18% reducing SDS-PAGE gel (see Note 21). Include a 
minus E1 reaction as a negative control. Place the finished gel onto filter paper that has just 
been soaked in ddH2O, then cover the gel with ddH2O soaked cellophane. Thoroughly dry 
the gel prior to autoradiography (see Note 8).  
10. Expose the dried gel to a phosphor screen then visualize with a molecular imager (Figures 
2.2A, 2.2B). 
11. Using your molecular imager’s software for quantitation, determine the amount of substrate 
and product (defined as any 32P-labeled band that migrates through the gel slower than the 
substrate) for each reaction. Use the area where product normally appears in the minus E3 
negative control as a measure of background levels using object average subtraction. Subtract 
this from all substrate and product bands and record the intensities of each. 
12. Divide the amount of product by the total signal for all products as well as substrate to 
calculate the percentage of substrate modified for each reaction. Next multiply the percentage 
by the starting concentration of substrate (5 μM), and then divide by both the concentration 
of SCF(βTRCP) (0.1 μM) and the time of the reaction. This provides the normalized rate of 
each reaction in units of minute-1. 
13. Using graphing software capable of fitting data to nonlinear equations, fit the data to the 
Michaelis-Menten equation where the E2 concentrations have been plotted on the X-axis and 
the normalized reaction rates have been plotted on the Y-axis. This procedure results in an 
estimate of the Michaelis constant, KM, as well as Vmax, the maximal reaction velocity under 
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saturating conditions of E2 for SCF(βTRCP) (Table 2.1). Note that the KM may vary both 
with storage conditions depending on the E2 used as well as with the nature of the substrate 
(Table 2.1; see Notes 12 and 22). If all steps are followed carefully, an r2 of 0.9 for duplicate 




Table 2.1 Affinities of E2s for SCF under various storage and reaction conditions. The KM values 
of Cdc34 or UbcH5 for SCF were measured as a function of both the ionic strength of the 





Cdc34, 100 μM 1.9 μM ± 0.1 μM 
Cdc34, 100 μM, 40% ddH2O 6.7 μM ± 1.0 μM 
Cdc34, 300 μM 4.1 μM ± 0.4 μM 
Cdc34, 1 mM 3.7 μM ± 0.2 μM 
Cdc34, 1 mM, single freeze-thaw cycle 4.2 μM ± 0.3 μM 
Cdc34, 1 mM, five freeze-thaw cycles 8.0 μM ± 0.7 μM 
Cdc34, 100 μM, β-cat-(Ub)1 320 nM ± 50 nM 
UbcH5, 100 μM 420 nM ± 30 nM 
UbcH5, 1 mM 330 nM ± 50 nM 




Figure 2.2 Determining the affinity of an E2 for an E3. (A) Autoradiogram of ubiquitylation 
reactions containing a 2-fold dilution series of Cdc34. Each lane corresponds to a reaction 
incubated for 8 minutes prior to quenching in 2x reducing quench buffer. (B) Same as (A) but 
using β-cat-(Ub)1 substrate. Each reaction was incubated for 2.5 minutes prior to quenching in 2x 
reducing quench buffer. The asterisk indicates a contaminant band whose signal was removed 
during background correction. (C) nonlinear regression of the reaction velocities from (A) fit to 
the Michaelis-Menten equation. (D) same as (C) except the reaction velocities from (B) were 









1. Purifying ubiquitin does not require the use of PIC. 
2. These protocols were written for the use of gravity flow disposable desalting columns with a 
bed volume of 5 mL. Volumes may be adjusted as needed to support the use of other 
products such as buffer exchange spin columns or dialysis kits. 
3. Cullin-RING ligases (CRLs) are modified by the ubiquitin-like protein Nedd8, which 
enhances both E2 binding as well as the rate of ubiquitin transfer from E2 to E3-bound 
substrate. In CRLs containing the Cul1 subunit (e.g. SCF), modification with Nedd8 occurs 
on Lys 720 on Cul1. Since UbcH5 can ubiquitylate Lys 720 in vitro that also results in 
activation of the E3, the Lys 720 to Arg mutation has been incorporated to suppress this. 
4. The β-cat peptide sequence is: N-term KAWQQQSYLD-phosphoS-GIH-phosphoS-
GATTTAPRRASY and contains a C-terminal PKA phosphorylation site for radiolabeling 
(Saha, 2008). While there are multiple commercial vendors that can, in principle, produce 
this peptide, our experience has been that the peptide is not trivial to synthesize. We have had 
good results with New England Peptide. 
5. K48R and D77 ubiquitin are described as donor and acceptor ubiquitins in the context of 
Cdc34 reactions because the E2 has a strong preference for forming poly-ubiquitin chains 
that are covalently linked through Lys 48 on ubiquitin. Therefore, K48R ubiquitin may still 
be thioesterified to Cdc34 but inhibits poly-ubiquitin chain formation. While D77 ubiquitin 
has an intact Lys 48 residue, the additional aspartate residue at the C-terminus eliminates the 
possibility of charging by E1 onto the Cdc34 active site. Thus, only di-ubiquitin product will 
be formed when assays are performed with both K48R donor and D77 acceptor ubiquitins. 
This makes quantitation of substrate and product far simpler for this assay. 
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6. It is critical that the overnight thrombin digestion be performed on the eluate (e.g. not while 
still attached to resin) on ice. Any agitation, such as rotating, will likely lead to precipitation. 
Also, we recommend using Sigma bovine plasma thrombin for the digest (T7513). 
7. While normal plastic cellophane may be adequate, we use ultra clear cellophane from 
Research Products International Corp (order number 1080), which we believe reduces the 
likelihood of gel cracking during the drying procedure. 
8. It is critical to evenly dry the gel such that no cracks form. In our experience, it is critical to 
use a gel dryer that is connected to a dedicated vacuum system. 
9. Overnight cultures can be used instead of inoculating from a selective media plate. However, 
in our experience, the overnight culture must be optimized to still be in log phase growth 
immediately prior to inoculation of the 1 L cultures, and starting from fresh bacteria on an 
agar plate has been much easier. 
10. Ubiquitin is well-known for its remarkable stability. We have solubilized lyophilized 
commercial ubiquitin at concentrations of 3.5 mM for long-term storage without any notable 
reduction in activity after multiple freeze-thaw cycles. 
11. It is okay if the TEV digestion of Cdc34 does not go to completion. The additional Ni-NTA 
step will remove His6-TEV as well as any undigested His6-Cdc34 from the elution. If Cdc34 
digestion appears 100% complete by Coomassie blue staining, we then skip the Ni-NTA 
incubation step. However, only do this if your size exclusion column has sufficient resolution 
to separate Cdc34 from TEV protease. 
12. Human Cdc34 activity is sensitive to the concentration of stocks frozen for long-term storage 
as well as the number of freeze-thaw cycles. Do not freeze Cdc34 protein at a concentration 
higher than 150 μM. Additionally, we recommend using fresh Cdc34 protein that has only 
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been frozen once for results featured in a publication. UbcH5 is significantly more resistant 
to these effects than Cdc34 (see Table 2.1). However, when stored near 1 mM concentrations 
for years, the corresponding author has anecdotally observed a significant decline in activity 
as well (data not shown). 
13. In the past, a size exclusion chromatography step was used for polishing the purification of 
C/RNedd8 and for exchanging the protein into storage buffer. In our experience, this step 
doesn’t measurably improve the activity or the purity. However, it will significantly reduce 
the final yield of product, and for this reason we’ve eliminated this step in the purification. 
14. In our experience, C/RNedd8 is fairly resistant to both multiple freeze-thaw cycles and long-
term storage at -80 °C. However, an excess of three years of long-term storage may result in 
qualitative changes in activity including the extent of poly-ubiquitin chain lengths achieved 
during the reaction. While this issue may not have an effect on the multi-turnover reaction 
described here (which considers any substrate modified by one or more ubiquitins as 
product), it could affect the results from experiments that quantify individual rates of 
ubiquitin transfer such as single-encounter reactions under pre-steady state conditions 
(Pierce, Kleiger, Shan, & Deshaies, 2009). 
15. Repeated rounds of size exclusion chromatography may result in pure product in the absence 
of a His6-tagged peptide, although shorter peptide substrates may result in insufficient 
separation of unmodified substrate from the mono-ubiquitylated product. 
16. The amount of K48R ubiquitin (e.g. donor) should be in at least 2-fold excess over the E2 
concentration to ensure that the E2 remains charged with ubiquitin throughout the time 
course, and in the presence of E3 a 5-fold excess should be considered minimum. However, 
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changing from a 5-fold to a 10-fold excess does not substantially affect the rate both in the 
absence or presence of E3. 
17. The rates (kobs) determined from this method do not represent the maximal rate of di-
ubiquitin formation since acceptor ubiquitin has a KM for Cdc34 greater than 1 mM. Thus, 
changing acceptor ubiquitin concentration by 2- or 3-fold should result in linear changes to 
kobs. This note is useful if the researcher wants to either reduce or increase the length of the 
time-points for any reason while still maintaining adequate product formation for 
quantitation.  
18. β-cat peptides contain two phosphoserines that are critical for binding to βTRCP. In our 
experience, these peptides are relatively impervious to freeze thaw cycles, but their 
phosphate modifications may slowly hydrolyze in solution so samples should be kept on ice 
and frozen immediately after use. 
19. Cdc34’s affinity for SCF(βTRCP) is mediated through electrostatic interactions, causing it to 
be sensitive to changes in the ionic strength of the final reaction conditions after all 
components have been added (Kleiger, 2009). All experiments were performed with a 
consistent ratio of ddH2O to other reaction components (55% of the final reaction volume), 
unless otherwise noted. It is important to be consistent and consider the amount of storage 
buffer being added to the reaction from other protein components when designing the 
conditions for these assays. For instance, note that replacing 15% of the total water in the 
reaction with storage buffer results in a significant increase in the KM (Table 2.1). It is 
important to consider that some E2s other than Cdc34 may also be sensitive to reaction 
conditions such as the ionic strength, concentration of glycerol, etc. 
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20. The combination of Cdc34 with SCF(βTRCP) results in the rapid production of di-ubiquitin 
product. Thus, allowing a reaction to sit for too long prior to adding substrate can result in a 
significant amount of free ubiquitin being consumed in the formation of di-ubiquitin, 
potentially interfering with the reaction. 
21. 18% polyacrylamide gels best resolve substrate peptide from a mono-ubiquitylated product. 
22. The identity of the substrate and the rate of ubiquitin transfer to that substrate can have 
substantial effects on the value of Km. For instance, note that the values for the KM of Cdc34 
for SCF do not agree when comparing reactions containing β-cat or β-cat-(Ub)1  as substrates 
(Figure 2.2 and Table 2.1). Thus, great care should be taken in selecting a substrate that is 
appropriate for Michaelis-Menten kinetics.  
23. For assays that estimate the KM of Cdc34 for SCF(βTRCP) and containing Cdc34 and β-cat 
substrate, the E1 concentration must be at least 1.0 μM. When the E1 concentration is lower 
than 1.0 μM, reactions containing the highest concentrations of Cdc34 will have higher ratios 
of uncharged Cdc34 to Cdc34-ubiquitin complex. This will lower the reaction velocities and 
results in the false appearance that E2 saturation of E3 has been achieved. This is often 
indicated during the fitting procedure by an r2 value much lower than 0.9. For reasons 
unknown, reactions containing UbcH5 at concentrations up to 30 μM can tolerate E1 
concentrations substantially below 1.0 μM. Similarly, Cdc34 can tolerate lower E1 
concentrations with β-cat-(Ub)1 substrate. In our experience, it is best to scout for conditions 
where the amount of ubiquitin or E1 doesn’t limit E2 or E3 activity. 
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MECHANISM OF LYSINE 48 SELECTIVITY DURING POLY-UBIQUITIN CHAIN 
FORMATION BY THE UBE2R1/2 UBIQUITIN-CONJUGATING ENZYME2 
3.1 Abstract 
Lysine selectivity is of critical importance during poly-ubiquitin chain formation because 
the identity of the lysine controls the biological outcome. Ubiquitins are covalently linked in 
poly-ubiquitin chains through one of seven lysine residues on its surface and the C-terminus of 
adjacent protomers. Lys 48 linked poly-ubiquitin chains signal for protein degradation; however, 
the structural basis for Lys 48 selectivity remains largely unknown. The ubiquitin-conjugating 
enzyme Ube2R1/2 has exquisite specificity for Lys 48, and ab initio docking of Ube2R1/2 and 
ubiquitin predicts that Lys 48 is guided to the active site through a key electrostatic interaction 
between Arg 54 on ubiquitin and Asp 143 on Ube2R1/2. The validity of this interaction was 
confirmed through biochemical experiments. Since structural examples involving Arg 54 in 
protein–ubiquitin complexes are exceedingly rare, these results provide additional insight into 
how ubiquitin–protein complexes can be stabilized. We discuss how these findings relate to how 
other ubiquitin-conjugating enzymes direct the lysine specificity of poly-ubiquitin chains.  
 
 
                                                          
2 This chapter was adapted from a published work:  
Hill S., Harrison J. S., Lewis S. M., Kuhlman B., Kleiger G. (2016). Mechanism of Lysine 48 
Selectivity during Polyubiquitin Chain Formation by the Ube2R1/2 Ubiquitin-Conjugating 




 The assembly of poly-ubiquitin chains onto proteins is a critical signaling process that is 
required for eukaryotic cellular homeostasis. Poly-ubiquitin chain synthesis is initiated when 
ubiquitin, a highly conserved 76 amino acid protein, is activated by ubiquitin-activating enzyme 
(E1). In an ATP-dependent process, E1 forms a high energy thioester bond to the C-terminus of 
ubiquitin. Next, the ubiquitin is transferred from E1 to a ubiquitin-conjugating enzyme (E2). 
Finally, a ubiquitin ligase (E3) recruits both the E2~ubiquitin complex as well as a protein 
substrate. E3s in the RING family stimulate the transfer of ubiquitin from the E2 to a lysine 
residue on the substrate (Branigan et al., 2015; Calabrese et al., 2011; Dou, Buetow, Sibbet, 
Cameron, & Huang, 2012; Plechanovová, Jaffray, Tatham, Naismith, & Hay, 2012; Pruneda et 
al., 2012; Scott et al., 2014; Das et al., 2013; Vittal, Stewart, Brzovic, & Klevit, 2015). This 
results in the formation of an isopeptide bond between ubiquitin’s C-terminus and the amino 
group on lysine side chains (Deshaies & Joazeiro, 2009).  
 During the process of RING class E3-catalyzed ubiquitylation, ubiquitin serves two 
major roles: it serves as a donor when an E2 transfers the ubiquitin from its active site to a 
protein substrate bound to an E3, and it serves as an acceptor when ubiquitin conjugated to 
substrate attacks an E2~donor ubiquitin. Ubiquitin contains seven lysine residues located on its 
surface, and consecutive ubiquitins in a poly-ubiquitin chain are either covalently linked between 
one of these lysines or the N-terminal amino group on an acceptor ubiquitin and the C-terminus 
of the donor. The identity of the lysine residue that tethers ubiquitins in the chain is of critical 
importance since different linkage types can signal alternative biological outcomes (Komander & 
Rape, 2012). For instance, a protein modified with Lys 48-specific poly-ubiquitin chains is 
targeted to the 26S proteasome for its degradation, whereas Lys 63-specific chains can promote 
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intra-cellular trafficking to endocytic vesicles or protein-protein interactions (Chau et al., 1989; 
Dikic, Wakatsuki, & Walters 2009; Hicke, Schubert, & Hill, 2005).  
 Lys 48-linked chains are the predominant chain type in human cells that promote protein 
degradation, and the human E2s Ube2K, Ube2G1/2, and Ube2R1/2 (which has historically been 
referred to as Cdc34) are known to assemble poly-ubiquitin chains onto protein substrates with 
Lys 48 specificity (Kim et al., 2011). Ubc1, the S. cerevisiae ortholog of Ube2K, has three 
critical residues, Thr 84, Gln 122 and Ala 124, that were identified on the E2 surface that interact 
with an acceptor ubiquitin to direct Lys 48 to the Ubc1 active site (Rodrigo-Brenni, Foster, & 
Morgan, 2010). More recently, it was found that Ube2K forms an electrostatic interaction 
between Glu 51 on acceptor ubiquitin and a Lys residue on the E2 surface (Middleton & Day, 
2015). Ube2G2 has been shown to form homo-dimers that may help direct Lys 48 to its active 
site (Liu et al., 2014). Ube2R1/2 is a critical E2 that functions with the cullin–RING ubiquitin 
ligases, and together these enzymes may be responsible for 20 percent of all proteasome-
dependent degradation in human cells (Deshaies & Joazeiro, 2009; Petroski & Deshaies 2005a; 
Soucy et al., 2009). Ube2R1/2 contains an atypical insertion distal to its active site that contains 
several conserved acidic residues (Arrigoni, Bertini, Gioia, & Papaleo, 2014; Choi et al., 2015; 
Gazdoiu, Yamoah, Wu, & Pan, 2007; Papaleo et al., 2012; Papaleo et al., 2011; Ziemba et al., 
2013), and this acidic loop has also been shown to have an important role in Lys 48 selectivity 
(Chong et al., 2014; Petroski, 2005b). More recent work has identified a loop on acceptor 
ubiquitin that contains residues that interact with the E2 in order to help place Lys 48 in the E2 
active site (Chong et al., 2014). Despite these advances, a detailed molecular characterization 
showing how an E2 achieves Lys 48 specificity during poly-ubiquitin chain synthesis is lacking.  
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 Here we show that human Ube2R1/2 forms a critical salt-bridge interaction between a 
conserved aspartic acid residue on Ube2R1/2 and acceptor ubiquitin residue Arg 54, and 
perturbation of this interaction leads to the severe loss of UbeR2 activity. Our results also 
provide new insight into how the Ube2R1/2 acidic loop may participate in catalysis, specifically 
through the formation of stabilizing interactions with the E3 as well as the donor ubiquitin.   
3.3 Materials and methods 
3.3.1 Molecular modeling 
3.3.1.1 Building initial models 
All of the molecular modeling steps were carried out using several protocols in the 
Rosetta molecular modeling suite (Leaver-Fay, 2011). To construct initial Ube2R1–Rbx1 
models, Rbx1 (PDB ID:2LGV (Spratt, Wu, Kovacev, Pan, & Shaw, 2012) and Ube2R1 (PDB 
ID:4MDK (Huang et al., 2014) were aligned to the respective components from the 
Ube2G2/Rnf45 co-crystal structure (PDB ID:2LXP (Das et al., 2013) followed by using the 
Rosetta relax (Conway, Tyka, DiMaio, Konerding, & Baker, 2014) and fixbb algorithms 
(Kuhlman & Baker, 2000). An initial closed acidic loop (residues 97-115) was built next onto the 
top-scoring Ube2R1–Rbx1 model using the CCD algorithm with fragments derived from the 
Ube2R1 amino acid sequence (Canutescu & Dunbrack, 2003). This model of the Ube2R1–Rbx1 
complex was used to create initial models of the Ube2R1–donor ubiquitin/acceptor ubiquitin–
Rbx1 complex using the UBQ_E2_thioester protocol, which allows the user to sequentially 
model the orientation of the thioesterified donor ubiquitin, the approach of an acceptor ubiquitin, 
and perform standard loop modeling on the acidic loop (Saha, Lewis, Kleiger, Kuhlman, & 
Deshaies, 2011). To preorder the donor ubiquitin tail in a conformation consistent with previous 
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E2/RING-E3 structures, the ubiquitin molecule was extracted from a co-crystal structure 
containing ubiquitin thioesterified to UbcH5b/Birc7 (PDB ID:4AUQ (Dou et al., 2012). The 
acceptor ubiquitin was based on an apo structure (1UBQ (Vijay-Kumar, Bugg, & Cook, 1987). 
To generate models consistent with the crystallized orientation of donor ubiquitin, a constraint 
was implemented between Leu 129 on Ube2R1 and both Ile 44 and Val 70 on the donor 
ubiquitin. Using this procedure, 4,000 theoretical models of Ube2R1–donor ubiquitin/acceptor 
ubiquitin–Rbx1 were generated yielding 286 low scoring models. The executable and flags for 
running the protocol can be found at www.rossetta.org. The subsequent models were clustered 
upon the acceptor ubiquitin position using a 4Å cut off, yielding 14 clusters of acceptor ubiquitin 
approach.  
3.3.1.2 Refining the acceptor ubiquitin 
To refine the acceptor ubiquitin position, the refinement option of the Rosettadock 
protocol was used with a constraint holding the ε-amino group on Lys 48 near the backbone 
carbonyl carbon atom of Gly 76 on the donor ubiquitin (Chaudhury, 2011). Additionally, as 
consistent with the experimental data, ambiguous constraints between Arg 54’s three 
guanidinium nitrogen atoms in acceptor ubiquitin and Asp143’s two carboxyl oxygen atoms in 
Ube2R1 were implemented. Using this procedure, 1,000 models were generated and the lowest 
scoring 1% were selected, yielding an ensemble of acceptor ubiquitin positions. The flags used to 
execute the Rosetta docking protocol can be found at www.Rosetta.org. 
3.3.1.3 Acidic loop refinement 
During the modeling efforts, a structure of Rbx1 in complex with Ubc12 oxyesterified to 
Nedd8 was published (PDB ID 4P5O (Scott et al., 2014), and therefore Rbx1 from this co-crystal 
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was used to regenerate the Ube2R1–Rbx1 complex followed by more extensive modeling of the 
Ube2R1 acidic loop. Based on the results from the charge-swapped mutations between Arg 91 
on Rbx1 and Asp 102 on Ube2R1, ambiguous constraints were implemented between Arg 91’s 
three guanidinium nitrogen atoms and Asp 102’s two carboxyl oxygen atoms. To more 
effectively sample conformational space, the "next-generation KIC" options were used, allowing 
backbone flexibility for Ube2R1 residues 100-115 (Stein & Kortemme, 2013). These results 
produced a variety of possible orientations and low scoring representative models were selected 
from the ensemble. The flags used to execute the next-generation KIC loop modeling protocol 
can be found at www.Rosetta.org. 
3.3.2 Protein expression and purification 
 Human E2s and ubiquitin constructs were expressed in Rosetta (DE3) bacterial cells 
(EMD Millipore). While Ube2R1 was used for structural modeling owing to the availability of x-
ray structures, Ube2R2 protein was used for the subsequent biochemical analysis. Note that 
Ube2R1 and Ube2R2 share greater than 90 % amino acid sequence identity within the catalytic 
domain, and the biochemical activities of these proteins are identical (G. Kleiger and R. 
Deshaies, unpublished data). E1 and βTrCP–Skp1 complex were expressed and purified from 
Hi5 insect cells as previously described (Kleiger et al., 2009; Saha et al., 2008). Cul1-Rbx1 was 
expressed and purified according to the “Split-n-Coexpress” method (Li et al., 2005). Proteins 
were purified with N-terminal poly-histidine (His)6- or glutathione-S-transferase (GST) tags on 
Nickel-NTA agarose beads (Qiagen) or Glutathione Sepharose 4B beads (GE Healthcare), 
respectively. Acceptor ubiquitin and the ubiquitin constructs used in the SCF-dependent 
ubiquitylation reactions had a non-cleavable (His)6- affinity tag; otherwise tags on the proteins 
were removed prior to gel filtration with TEV or thrombin protease. All ubiquitin and E2 
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proteins were subjected to gel filtration on a Superdex 75 10/300 column (GE Healthcare). Cul1-
Rbx1 proteins were first purified by cation exchange chromatography before gel filtration on a 
Superdex 200 10/300 column. All purified proteins were stored in a buffer containing 30 mM 
Tris-Cl (pH 7.5), 100 mM NaCl, 10% glycerol, and 1 mM DTT, except for those used in 
chemical cross-linking assays, which lacked DTT. Proteins were flash frozen in liquid nitrogen 
prior to storage at -80°C and were never subjected to multiple freeze-thaw cycles. All Cul1-Rbx1 
proteins were neddylated and purified as previous described (Saha & Deshaies, 2008). β-catenin 
peptide was purchased from New England Biolabs and identical to peptides used in previous 
studies, and mono-ubiquitylated peptides were also generated and purified using previously 
described methods (Saha & Deshaies, 2008). 
3.3.3 Di-ubiquitin synthesis assay 
 Di-ubiquitin synthesis was performed in a reaction buffer containing 30 mM Tris-Cl (pH 
7.5), 100 mM NaCl, 5 mM MgCl2, 2 mM ATP, and 2 mM DTT. 32P-labeled K48R donor 
ubiquitin (5 μM) was first incubated with E1 enzyme (0.5 μM) for 2 minutes. Ube2R2 (2 μM) 
was then added and incubated for a further 2 minutes. The reaction was initiated by the addition 
of acceptor ubiquitin (50 μM) that contained an additional Asp residue at its C-terminus (this is 
referred to as D77 ubiquitin that cannot be thioesterified to Ube2R2). Time points were collected 
and quenched by the addition of reducing SDS-PAGE loading buffer. Reactions were resolved 
on 4-20% SDS-PAGE gels (Lonza), dehydrated, and exposed to a phosphor screen. The 
reactions were imaged using a Typhoon 9410 scanner and the amounts of substrate and product 
were quantified using ImageQuant software (GE Healthcare). Specifically, the amount of 
product was quantified by dividing the amount of di-ubiquitin by the total signal per lane, and 
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then normalized by multiplying by the ratio of the concentrations of donor ubiquitin and 
Ube2R2. The rate of product formation was then determined by linear regression.   
3.3.4 Multi-turnover ubiquitylation assays 
 Multi-turnover ubiquitylation reactions were performed using β-catenin peptide as 
substrate. Unlabeled ubiquitin (60 μM) was charged with E1 (1 μM) for 2 minutes in a reaction 
buffer that was identical to the di-ubiquitin synthesis assay. E2 (10 μM) was then added and 
incubated for 2 minutes, followed by the addition of neddylated SCFβ-TrCP (0.1 μM). 32P-
labeled substrate (5 μM) was added to the reaction and time points were collected and quenched 
using reducing SDS-PAGE loading buffer. Reactions containing Ube2D3/UbcH5c were resolved 
on 15% SDS-PAGE gels, whereas all others were resolved on 4-20% gels.  
 The KM values of E2 constructs for SCF were determined as follows. Ubiquitylation 
reactions were assembled to contain a 2-fold dilution series of each E2 protein while the 
remaining reaction components were identical as described above. The highest concentration of a 
given E2 and the time of incubation for the ubiquitylation reactions were determined to ensure 
that the amounts of substrate conversion did not exceed 20%. The fractions of substrates 
converted to products were quantified by dividing all ubiquitylated products by the total signal 
including substrate, and normalized by multiplying by the ratio of the concentrations of β-catenin 
peptide and SCF. The reaction rates were then estimated by dividing the normalized fractions of 
substrates converted to products by the time of incubation. The reaction velocities were plotted 
as a function of E2 concentration and were fit to the Michaelis-Menten equation using non-linear 




3.3.5 Single-encounter quench flow 
 Single-encounter ubiquitylation assays were performed using a KinTek RQF-3 Rapid 
Quench-Flow. Ube2R2 (20 μM) was charged in the presence of (His)6-tagged R54D ubiquitin 
(30 μM), E1 (1 μM), and reaction buffer, followed by the addition of unlabeled β-catenin peptide 
(200 μM). This reaction was then mixed equally with SCF (1 μM) that had been pre-incubated 
with 32P-labeled Ub-β-catenin peptide (0.2 μM). Reactions were quenched in reducing SDS-
PAGE buffer and substrate and products were resolved on a 4-20% gradient SDS-PAGE gel. 
Reactions were run in duplicate and each product band was quantified as a percentage of the 
signal from the total lane for each time point. The rates of ubiquitin transfer and substrate 
dissociation from SCF were determined using both KinTek Explorer global fitting software and 
non-linear curve fitting to analytical closed-form solutions. (Pierce et al., 2009). 
3.4 Results  
 To explore the molecular basis for Lys 48 poly-ubiquitin chain synthesis, molecular 
models of Ube2R1 were generated in complex with a donor ubiquitin thioesterified to the 
Ube2R1 active site, an acceptor ubiquitin with Lys 48 constrained to the active site, and the 
Rbx1 subunit of the Skp1-Cullin-Fbox (SCF) ubiquitin ligase. Ube2R1/2 was chosen because: 
(1) of its critical importance to cellular homeostasis; (2) it forms poly-ubiquitin chains with 
exquisite Lys 48 specificity; and (3) previous modeling efforts elucidated the conformation of 
the Ube2R1–donor ubiquitin interface that was subsequently confirmed by x-ray crystallography 
(Petroski & Deshaies, 2005b; Ceccarelli et al., 2013; Saha et al., 2011). The orientation of the 
acidic loop has been previously characterized by molecular dynamics and was also included 
during the modeling procedure (Papaleo et al., 2011).  
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 Molecular modeling of the Ube2R1–donor ubiquitin/acceptor ubiquitin–Rbx1 complex 
resulted in 14 distinct clusters of the Ube2R1–acceptor ubiquitin conformation (Figure 3.1). To 
distinguish between the theoretical models, compensatory charge-swapped mutations were 
introduced in Ube2R2 and ubiquitin that individually should disrupt the interface and result in 
decreased Ube2R2 activity; however, in combination the mutant Ube2R2 and ubiquitin proteins 
should restore the interface and product formation. 
3.4.1 A salt bridge between acceptor ubiquitin and Ube2R1/2 
 Ube2R2 activity was characterized using a previously established, simplified 
ubiquitylation assay in the absence of E3 (Figure 3.2A). Ube2R2 was first thioesterified to 
radiolabeled donor ubiquitin, and the reaction was initiated by the addition of unlabeled acceptor 
ubiquitin resulting in a di-ubiquitin product. 
 A previous study had shown that acceptor ubiquitin residue Arg 54 participated in 
Ube2R1-catalyzed Lys 48 poly-ubiquitin chain formation (Chong et al., 2014). Consistent with 
this, the mutation of Arg 54 to an Asp residue in acceptor ubiquitin led to a 52-fold reduction in 
Ube2R2 activity as compared with WT ubiquitin (Figures 3.2B, 3.2C and Table 3S.1). Models 
from one of the 14 clusters predicted the formation of a salt bridge between Arg 54 and Ube2R1 
residue Asp 143. To determine if Asp 143 may interact with Arg 54 on ubiquitin, D143K 
Ube2R2 protein was expressed and purified (note that lysine was chosen for the charge swap 
instead of arginine since the Rosetta algorithm identified this and R54D ubiquitin as the most 
energetically favorable compensatory mutant pair). Consistent with this, D143K Ube2R2 activity 
with WT acceptor ubiquitin was reduced by 7-fold in comparison with WT Ube2R2 (Figures 




Figure 3.1 Results of the clustering analysis of the acceptor ubiquitin. Initial modeling effort 
used with the UBQ_E2_thioester protocol. This analysis produced 14 clusters. The Cα atoms for 
Ube2R1 Asp 143 and acceptor ubiquitin Arg 54 are depicted as red spheres. Cluster 3 permits 







acceptor ubiquitin resulted in only a 4-fold loss of Ube2R2 activity compared to WT Ube2R2 
and acceptor ubiquitin. Thus, the pairing of D143K Ube2R2 and R54D acceptor ubiquitin nearly 
restored Ube2R2 activity to WT levels despite the presence of the R54D mutation in ubiquitin.  
 The chain linkage type for the di-ubiquitin product formed in the reaction containing 
D143K Ube2R2 and R54D acceptor ubiquitin was likely specific for Lys 48. Note that while 
Ube2R1/2 shows high fidelity for generating Lys 48 specific poly-ubiquitin chains, it is capable 
of generating non-Lys 48 chain linkages in the presence of K48R acceptor ubiquitin (Gazdoiu et 
al., 2007; Petroski & Deshaies, 2005b). The recovery of D143K Ube2R2 activity was eliminated 
in the presence of K48R/R54D acceptor ubiquitin, indicating Lys 48 specificity (Figure 3.3).  
Based on these results, molecular models of the acceptor ubiquitin approach were refined 
using a constraint between Ube2R1 residue Asp 143 and acceptor ubiquitin residue Arg 54. This 
effort resulted in an ensemble of acceptor ubiquitin approaches (Figures 3.4A, 3.4B) and allowed 
for several important observations. First, the highly conserved Ube2R1/2 residues Tyr 87, His 98 
and Ser 138, which all had previously been shown to have catalytic roles during poly-ubiquitin 
chain formation, were localized near Lys 48 on acceptor ubiquitin and the Ube2R1 active site 
(Figure 3.4C)(Gazdoiu et al., 2007). Secondly, Ile 44 on acceptor ubiquitin, a residue that 
typically is important in the stabilization of protein-protein interactions involving ubiquitin, was 
not participating in the Ube2R1–acceptor ubiquitin interface (Figure 3.4C). Consistent with this 
latter observation, mutation of Ile 44 to either an Ala or Arg residue led to only 3- and 2-fold 
reductions in Ube2R2 activity respectively (Figure 3.5A and Table 3S.1). This result is all the 
more striking given that Ile 44 has been shown to stabilize the docking of donor ubiquitin to 





Figure 3.2 The double mutant cycle of R54D ubiquitin and D143K Ube2R2. The results 
demonstrate that each mutant is individually defective but in combination complement each 
other during Ube2R2 catalysis. (A) Schematic showing the components and order of addition for 
the di-ubiquitin synthesis assay. (B) Time course for the di-ubiquitin synthesis assay and all four 
combinations of the R54D ubiquitin and D143K Ube2R2 double mutant cycle. Representative 
data are shown. (C) Graph plotting the quantitation of the amounts of di-ubiquitin product in (B) 




Figure 3.3 Di-ubiquitin synthesis assay demonstrating Lys 48 specificity. Time course showing 
that reactions containing K48R/R54D acceptor ubiquitin and WT or D143K Ube2R2 resulted in 
similar amounts of product formation, whereas the reaction containing R54D acceptor ubiquitin 
and D143K Ube2R2 resulted in far greater product formation than the reaction containing WT 
Ube2R2 and R54D ubiquitin. The acceptor ubiquitin concentration was 100 μM.  
 
 
 If Asp 143 on Ube2R1/2 interacts specifically with Arg 54 on acceptor ubiquitin, a 
charge-swapped mutation at a residue on the Ube2R1/2 surface not participating in the predicted 
Ube2R1–acceptor ubiquitin interface should not restore Ube2R1/2 activity in the presence of 
R54D acceptor ubiquitin. Ube2R1 residue Asp 91 was located on the periphery of the Ube2R1–
acceptor ubiquitin interface (Figure 3.4C), and D91K Ube2R2 activity was both comparable to 
WT Ube2R2 in the presence of WT acceptor ubiquitin and was also similarly defective in the 
presence of R54D acceptor ubiquitin (Figure 3.5B and Table 3S.1). Furthermore, a charge-
swapped mutation in Asp 58 on ubiquitin, a residue in close proximity to Arg 54, led to a 65-fold 
decrease in WT Ube2R2 activity, and product formation was even more defective in the presence 
of D143K Ube2R2 (Figure 3.5C and Table 3S.1). This result excludes the alternative hypothesis 
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that the D143K mutation suppresses R54D ubiquitin by converting Ube2R2 into a promiscuous 
enzyme.    
To further explore the nature of the putative Asp 143 Ube2R1/2 – Arg 54 ubiquitin 
interaction, D143A Ube2R2 and R54A acceptor ubiquitin proteins were expressed and purified. 
Specifically, if the interaction is deterministic in stabilizing the complex between Ube2R1/2 and 
acceptor ubiquitin, both D143A Ube2R2 and R54A acceptor ubiquitin should be defective in 
activity, whereas if the interaction is only permissive, these mutants should not lead to defects in 
activity. Product formation was defective in a reaction containing WT Ube2R2 and R54A 
acceptor ubiquitin, though less so than the reaction containing charge-swapped R54D ubiquitin 
(Figure 3.5D and Table 3S.1). Similarly, D143A Ube2R2 activity was compromised in the 
presence of WT ubiquitin and also to a lesser extent than for D143K Ube2R2. Finally, to 
determine whether Asp 143 can also be charge swapped with arginine in addition to lysine, 
D143R Ube2R2 was produced and had nearly identical loss of activity compared with D143K 
Ube2R2 as well as the ability to produce di-ubiquitin in the presence of R54D acceptor ubiquitin 
(Figure 3.5E and Table 3S.1). Taken together, these results suggest that Asp 143 on Ube2R1/2 





Figure 3.4 Molecular models constrain Arg 54 ubiquitin and Asp 143 Ube2R1 in proximity. (A) 
Ribbon diagrams for 10 models randomly selected from an ensemble derived from the acceptor 
ubiquitin refinement procedure. Nitrogen atoms on Arg 54 and Lys 48 are blue; oxygen atoms on 
Asp 143 are red. (B) Ribbon diagram of a representative model from the ensemble showing the 
entire Ube2R1–donor ubiquitin/acceptor ubiquitin complex. (C) Close up of the Ube2R1–
acceptor ubiquitin interface highlighting the locations of key residues that have previously been 
shown to participate in catalysis. Notice that Ube2R1 residue Asp 91 and acceptor ubiquitin 
residue Ile 44 are not located at the predicted Ube2R1–ubiquitin interface. Images were 
generated in Pymol. 
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   The significance of the Asp 143 Ube2R1/2 - Arg 54 acceptor ubiquitin ion pair was next 
examined within the context of a fully reconstituted, ubiquitylation reaction containing both 
ubiquitin ligase SCF and a physiologically relevant substrate bound to SCF. Multi-turnover 
ubiquitylation reactions were assembled with combinations of WT or mutant Ube2R2 and 
ubiquitin and a 32P-labeled β-Catenin peptide containing a single N-terminal lysine residue. The 
combination of WT Ube2R2 and ubiquitin in the SCF-dependent ubiquitylation reaction resulted 
in the formation of long poly-ubiquitin chains onto the β-Catenin peptide substrate, and the 
combination of WT Ube2R2 with R54D ubiquitin led to a substantial reduction in the number of 
ubiquitins contained within the chains (Figure 3.6). The combination of D143K Ube2R2 and WT 
ubiquitin also led to a reduction in the average lengths of the poly-ubiquitin chains compared to 
WT Ube2R2, although to a lesser extent as compared with WT Ube2R2 and R54D ubiquitin. 
Finally, the combination of D143K Ube2R2 and R54D ubiquitin resulted in longer poly-
ubiquitin chains attached to substrate in comparison with the reaction containing WT Ube2R2 




Figure 3.5 Di-ubiquitin synthesis assay does not validate other models. Experimental validation 
of the Ube2R1/2–acceptor ubiquitin complex confirming that Ile 44 on ubiquitin and Asp 91 on 
Ube2R2 do not help stabilize the interaction. (A) Time courses for di-ubiquitin synthesis 
comparing product formation for WT components with reactions containing WT Ube2R2 and 
I44R acceptor ubiquitin. (B) Same as in (A), except D91K Ube2R2 activity has been assessed in 
the presence of WT or R54D acceptor ubiquitin. (C) Same as in (A), except D58R acceptor 
ubiquitin activity has been assessed in the presence of either WT or D143K Ube2R2. (D) Same 
as in (A), except R54A acceptor ubiquitin activity has been assessed in the presence of WT 
Ube2R2, or D143A Ube2R2 activity in the presence of WT ubiquitin. (E) Same as in (A), except 
D143R Ube2R2 activity has been assessed in the presence of either WT or R54D acceptor 




Figure 3.6 Arg 54 is qualitatively rescued by Asp 143 under multi-turnover SCF assay. Multi-
turnover ubiquitylation reactions with SCF demonstrate that the presence of R54D ubiquitin 
diminishes the lengths of the poly-ubiquitin chains on product compared with WT ubiquitin, and 
that the introduction of D143K Ube2R2 with R54D ubiquitin substantially increases the lengths 
of the chains. Time courses for the ubiquitylation of β-catenin peptide for the entire double 
mutant cycle. Notice that some of the poly-ubiquitin chains in the reaction containing WT 
Ube2R2 and ubiquitin migrate as high molecular weight smears, and while these are still present 
in the reactions containing D143K Ube2R2, the intensities have shifted significantly lower in the 
direction of the substrate band.   
64 
 
 While poly-ubiquitin chain lengths were significantly reduced in reactions containing WT 
Ube2R2 and R54D ubiquitin in comparison with reactions containing WT proteins, it was 
surprising that poly-ubiquitin chains were formed on substrate that contained as many as ten 
R54D ubiquitins, especially considering that in the absence of SCF, WT Ube2R2 activity was 
reduced by 52-fold in the presence of R54D ubiquitin (Figure 3.2 and Table 3S.1). It would be 
ideal to estimate the individual rates of ubiquitin transfer from Ube2R2 to one or more ubiquitins 
on a SCF-bound substrate for comparison with the rates derived from the SCF-independent 
assay; however, this is not possible using the results from the multi-turnover reactions. To 
address in detail how the R54D mutation affects ubiquitin’s activity as an acceptor on a SCF-
bound substrate, the pre-steady state kinetics of the SCF-dependent ubiquitylation reaction were 
measured using a quenched-flow instrument in the presence of WT Ube2R2 and a mono-
ubiquitylated β-Catenin peptide substrate containing the R54D mutation.  
 Single-encounter ubiquitylation reactions were initiated in the presence of WT Ube2R2 
and R54D ubiquitin and the rates of ubiquitin transfer were estimated (Figures 3S.1). The rates 
for the first and second ubiquitin transfer events to substrate modified ubiquitins were 1.1 sec-1 
and 0.4 sec-1, respectively, which were considerably slower than the previously measured rates 
of ubiquitin transfer for WT proteins (4 sec-1 - 6 sec-1) (Pierce et al., 2009). Single-encounter 
ubiquitylation reactions containing identical substrate were then repeated in the presence of 
D143K Ube2R2 and R54D ubiquitin (Figure 3.7). In this case, the rates for the first, second and 
third ubiquitin transfers to SCF-bound substrate (10.3 sec-1, 3.6 sec-1, and 2.9 sec-1, 






Figure 3.7 Single-turnover SCF reactions quantitatively confirm Arg 54 – Asp 143 rescue. Pre-
steady state single encounter ubiquitylation reactions allow for the estimation of the individual 
rates of ubiquitin transfer from Ube2R2 to substrate modified ubiquitins bound to SCF, 
indicating that the rate of R54D ubiquitin transfer is substantially faster in the presence of 
D143K Ube2R2 in comparison with WT Ube2R2. (A) Time course showing the step-wise 
transfer of R54D ubiquitin to SCF-bound substrate in the presence of D143K Ube2R2. (B) 
Schematic showing the rates of ubiquitin transfer to substrate as well as the rates of substrate and 
product dissociation from SCF with D143K Ube2R2 and R54D acceptor ubiquitin. (C) Graph 
plotting either the disappearance of mono-ubiquitylated substrate (above) or the appearance of 
di-ubiquitylated product (below) over time in the presence of D143K Ube2R2. Error bars 





Also note that in the presence of SCF and WT Ube2R2, the reduction in the average rate 
of ubiquitin transfer when comparing WT and R54D ubiquitin was 8-fold; this is significantly 
less than the 52-fold reduction observed in the SCF-independent assay (Table 3S.1). This key 
observation provides additional evidence supporting the notion that the R54D mutation in 
acceptor ubiquitin affects binding to Ube2R2. 
3.4.2 The Ube2R1/2 acidic loop participates in binding to SCF.  
 Ube2R1/2 contains a conserved 12 amino acid insertion distal to the active site referred to 
as the acidic loop (owing to its four invariably conserved acidic residues), and previous studies 
have suggested an important role for the acidic loop in controlling Lys 48 specificity (Gazdoiu et 
al., 2007; Petroski & Deshaies, 2005b). The conformation of the acidic loop is highly flexible, 
and loop residues are disordered in all x-ray structures of Ube2R1 to date (Ceccarelli et al., 2011; 
Ceccarelli et al., 2013; Sheng et al., 2012). We reasoned that the presence of both donor and 
acceptor ubiquitins as well as Rbx1 during molecular modeling may limit the conformational 
space afforded to the acidic loop, and the models of the Ube2R1–donor ubiquitin/acceptor 
ubiquitin–Rbx1 complex were analyzed to explore how the acidic loop participates in Lys 48 
specificity.  
 Despite the presence of both ubiquitins and Rbx1, the modeling effort resulted in multiple 
conformations of the Ube2R1 acidic loop. Nevertheless, many of these models resulted in an 
interaction between Rbx1 residue Arg 91 and acidic loop residues Asp 102 and/or Asp 103 
(Figure 3.8). Indeed, the previous structural characterization of the Ube2R1–Rbx1 interface by 
NMR had identified Arg 91 as a critical residue in promoting Ube2R1 interaction with SCF 
(Spratt et al., 2012). To determine whether acidic loop residues may contact Arg 91 in Rbx1, 
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charge-swapped mutations were generated in Ube2R2 residues Asp 102 and Asp 103 as well as 
in Rbx1 residue Arg 91.  
 The affinities of Ube2R2 proteins for WT or mutant SCF were assessed in ubiquitylation 
assays by estimating the KM of Ube2R2 for SCF. The KM of WT Ube2R2 for WT SCF was 0.15 
μM, whereas the KM of Ube2R2 for SCFR91E Rbx1 was 5.4 μM, indicating a large decrease in 
the affinity of Ube2R2 for mutant SCF (Figures 3.9A, 3.10A, and Table 3S.2). To determine 
whether the defect in Ube2R2 binding by the R91E mutation in Rbx1 was specific to the acidic 
loop region, the KM of WT Ube2D3/UbcH5c, an E2 that does not contain an acidic loop, was 
determined for WT SCF as well as SCFR91E Rbx1, and in this case only a 2-fold difference was 
observed (Figures 3.9B, 3.10B, and Table 3S.2). Finally, the KM of D102K Ube2R2 for WT SCF 
was 0.49 μM, whereas the KM of D102K Ube2R2 for SCFR91E Rbx1 was 1.8 μM (Figures 3.9C, 
3.10C, and Table 3S.2). While the affinity of D102K Ube2R2 for SCFR91E Rbx1 is 
approximately 10-fold weaker in comparison with the affinity of WT Ube2R2 for SCF, the 
affinity of D102K Ube2R2 for SCFR91E Rbx1 is nevertheless 3-fold greater compared with WT 
Ube2R2 and mutant SCF, demonstrating a modest but significant restoration of D102K 





Figure 3.8 Molecular modeling predicts Ube2R1/2 acidic loop interactions with Rbx1. (A) 
Ribbon diagram of a representative model of the Ube2R1–donor ubiquitin/acceptor ubiquitin–
Rbx1 complex where Ube2R1 residue Asp 102 and Rbx1 residue Arg 91 are in close proximity. 
(B) Same as in (A) except Ube2R1 residue Asp 103 and Rbx1 residue Arg 91 are predicted to be 






Figure 3.9 Interaction between Asp 102 Ube2R2 and Arg 91 Rbx1. (A) Multi-turnover 
ubiquitylation reactions comparing the activities of WT SCF and SCFR91E Rbx1 in the presence 
of increasing concentrations of WT Ube2R2. Each lane represents a single ubiquitylation 
reaction that was incubated for 2 minutes prior to quenching. (B) Same as in (A) except titrations 
of Ube2D3/UbcH5c were performed in the presence of either WT SCF or SCFR91E Rbx1. (C) 
Same as in (A) except titrations of D102K Ube2R2 were performed in the presence of either WT 
SCF or SCFR91E Rbx1. (D) Same as in (A) except titrations of D103K Ube2R2 were performed 
in the presence of either WT SCF or SCFR91E Rbx1.  
 
 
 The possibility of an electrostatic interaction between Ube2R2 residue Asp 103 and Rbx1 
residue Arg 91 was also predicted by the modeling effort (Figure 3.8B); however, the KM values 
of WT and D103K Ube2R2 for WT SCF were similar, and the KM values of WT and D103K 
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Ube2R2 for SCFR91E Rbx1 were also similar (Figures 3.9D, 3.10D, and Table 3S.2). Taken 
together, these results suggest that Ube2R1/2 acidic loop residue Asp 102 forms an interaction 
with Rbx1 residue Arg 91 during Ube2R1/2–SCF complex formation, although it remains likely 
that Arg 91 may form additional interactions with other residues in the acidic loop since only a 




Figure 3.10 Plots of substrate ubiquitylation as a function of Ube2R2 concentration. Plots 
correspond to respective reactions found in Figure 3.9. Error bars represent the standard error of 
measurement from duplicate data sets. 
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 We next wanted to address the structural roles of the other 2 conserved acidic residues in 
the Ube2R1/2 acidic loop, Glu 108 and Glu 112, and determine how they may affect Lys 48 
specificity. Some 5,000 models of the Ube2R1–donor ubiquitin/acceptor ubiquitin–Rbx1 
complex were generated in which Ube2R1 residue Asp 102 and Arg 91 in Rbx1 were 
constrained to be in proximity; however, the position of the acidic loop was variable despite the 
constraint (Figure 3.11). The top 15 percent scoring structures were analyzed, and only 8 of the 
750 models predicted an interaction between Glu 108 and acceptor ubiquitin, and none of the 
models predicted an interaction between Glu 112 and acceptor ubiquitin. Instead of interacting 
with acceptor ubiquitin, approximately 50 percent of the top models predicted an interaction 
between either Glu 108 or Glu 112 and donor ubiquitin. Thus, molecular modeling suggests that 
Ube2R1/2 residues Glu 108 and Glu 112 may promote Ube2R1/2 function by interacting with 
the donor ubiquitin without directly influencing the conformation of the Ube2R1/2–acceptor 




Figure 3.11 Lowest scoring Ube2R1 acidic loop orientations. Generated from 10 models of the 
Ube2R1–donor ubiquitin/acceptor ubiquitin–Rbx1 complex randomly selected from 5,000 
trajectories. The acidic loops have been colored by a gray-scale gradient. These low scoring 
structures result in a variety of possible conformations that can make contacts with both Rbx1 




 A combined molecular modeling and double mutant cycle analysis has been used to 
elucidate the mechanism of Lys 48 specificity during poly-ubiquitin chain formation by the 
Ube2R1/2 ubiquitin-conjugating enzyme. These results uncover a potential electrostatic 
interaction between Arg 54 on acceptor ubiquitin and Asp 143 on Ube2R1/2; however, we 
acknowledge that more intricate models cannot be ruled out. For instance, Asp 143 and/or Arg 
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54 may form additional inter-molecular interactions at the complex interface, which potentially 
explains why the double mutant combination does not fully restore Ube2R2 activity. It is not 
surprising that Asp 143 may have an important role in Ube2R1/2 function as it is invariably 
conserved in Ube2R1/2 ortholog sequences. Furthermore, there is evidence that Arg 54 on 
ubiquitin is also important, since the replacement of endogenous ubiquitin with a R54D mutant 
in S. cerevisiae resulted in a mild slow growth phenotype (Roscoe, Thayer, Zeldovich, Fushman, 
& Bolon, 2013). When introduced into mammalian cells, expression of the double R54A/Y59A 
ubiquitin mutant led to cellular apoptosis (Chong et al., 2014). In combination with the results 
presented here, these results demonstrate the importance of ubiquitin residue Arg 54 both in vivo 
and in vitro.     
 The careful consideration of the rates of Ube2R2-catalyzed ubiquitin transfer either in the 
absence or the presence of SCF further supports the notion that acceptor ubiquitin residue Arg 54 
participates in promoting ubiquitin binding to Ube2R1/2. Mutations in ubiquitin that negatively 
affect binding to Ube2R1/2 (and not catalysis) can in principle be compensated for by increasing 
the ubiquitin concentration high enough to saturate Ube2R1/2. During analysis of the results for 
the SCF-dependent reactions, it was noted that the difference in the average rate of ubiquitin 
transfer in the presence of either WT or R54D ubiquitin was approximately 8-fold (Figure 3.7), 
significantly smaller than the difference in the rates of ubiquitin transfer in the SCF-independent 
assay (52-fold; Table 3S.1). One critical difference between these two assays is the acceptor 
ubiquitin concentration: in the SCF-independent assay (Figure 3.2A), the concentration of 
ubiquitin is 50 μM. In the SCF-dependent reaction, the simultaneous binding of both a substrate 
modified with an acceptor ubiquitin and Ube2R2 to SCF results in a substantial increase in the 
effective concentration of acceptor ubiquitin and Ube2R2 (previously estimated to be in the low 
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mM range (Petroski & Deshaies, 2005b). Considering that the KM of acceptor ubiquitin for 
Ube2R2 is approximately 1 mM, the increase in the effective concentration of acceptor ubiquitin 
for Ube2R2 is most likely suppressing the reduced affinity of Ube2R2 for R54D ubiquitin in the 
SCF-dependent assay (Ziemba et al., 2013). Thus, these results help explain why substantial 
poly-ubiquitin chains are formed onto a SCF-bound substrate in the presence of R54D ubiquitin 
during the multi-turnover reaction scheme (Figure 3.6). 
 Does the presence of an acidic residue on E2s at structurally equivalent positions to 
Ube2R1/2 residue Asp 143 determine lysine specificity during catalysis? Approximately one-
half of human E2 protein sequences contain either an aspartic or glutamic acid residue at 
positions that are aligned to Asp 143 in Ube2R1/2 in a multiple sequence alignment of E2 
paralogs. However, the presence of an acidic residue at this position does not necessarily 
determine the lysine specificity of poly-ubiquitin chains. For instance, Ube2S is an E2 that forms 
poly-ubiquitin chains with Lys 11 specificity, and though Glu 132 in Ube2S is structurally 
equivalent to Asp 143 in Ube2R1/2, a mutation in Glu 132 was not shown to disrupt Ube2S 
activity (Wickliffe, Lorenz, Wemmer, Kuriyan, & Rape, 2011). Furthermore, the E2s that 
modify protein substrates with the ubiquitin-like proteins Nedd8 and SUMO also contain acidic 
residues at positions that are structurally equivalent to Ube2R1/2 residue Asp 143; however, 
these E2s do not assemble chains of Nedd8 or SUMO. 
 A survey of the Protein Data Bank for structures of proteins in complex with ubiquitin 
indicates that electrostatic interactions between a protein and ubiquitin residue Arg 54 are highly 
atypical (Harrison, Jacobs, Houlihan, Van Doorslaer, & Kuhlman, 2016). Indeed, only 3 
examples were found, each involving the interaction of a de-ubiquitylating enzyme and ubiquitin 
(PDBs 3IHP, 4DHJ, and 4BOZ) (Mevissen et al., 2013; Wiener et al, 2013). On the other hand, 
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electrostatic interactions involving other charged residues have been shown to have important 
roles in determining the lysine specificity of poly-ubiquitin chains by also stabilizing protein–
ubiquitin interactions. For instance, Ube2S forms poly-ubiquitin chains with Lys 11 specificity 
by stabilizing the Ube2S–ubiquitin interaction through a salt-bridge between Lys 6 on ubiquitin 
and Glu 131 on Ube2S (Wickliffe et al., 2011). Interestingly, the yeast E2 Ubc1, which like 
Ube2R1/2 forms Lys 48 specific poly-ubiquitin chains, utilizes a polar cluster of residues near its 
active site that are not conserved in Ube2R1/2, and the human ortholog Ube2K forms an 
electrostatic interaction between Glu 51 on ubiquitin and a Lys residue on Ube2K (Middleton et 
al., 2015; Rodrigo-Brenni et al., 2010). Thus, it appears that Ube2R1/2 and Ubc1/Ube2K 
generate Lys 48 linked poly-ubiquitin chains through distinct mechanisms.  
 In addition to Lys 48 and Lys 11 specific poly-ubiquitin chains, the mechanism 
describing how Lys 63 specificity is achieved by an E2 has also been elucidated (Branigan. 
Plechanovová, Jaffray, Naismith, & Hay, 2015; Eddins, Carlile, Gomez, Pickart, & Wolberger, 
2006). In this case, the E2 Ubc13 forms a heterodimer with its binding partner Mms2. Ubc13 
contains the active site that participates in catalysis, while Mms2 has a ubiquitin binding site that 
places Lys 63 within close proximity of the Ubc13 active site. In summary, it is clear that while 
only a small number of examples of how E2s determine lysine specificity during poly-ubiquitin 
chain formation are known, a diverse repertoire of mechanisms exist in nature.  
  We also used our modeling approach to help ascertain how the four highly conserved 
Ube2R1/2 acidic loop residues participate in determining lysine specificity during poly-ubiquitin 
chain formation. Rather than forming direct interactions with the acceptor ubiquitin, it appears 
that the acidic loop residues interact with either SCF or with the donor ubiquitin. In support of 
this, note that we had previously generated a human Ube2R2 mutant protein in which all four 
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acidic residues were mutated to alanine, and while the activity of this mutant was severely 
defective, it was still capable of forming poly-ubiquitin chains onto a SCF-bound substrate with 
Lys 48 specificity (Ziemba et al., 2013). Secondly, models of the Ube2R1–donor 
ubiquitin/acceptor ubiquitin–Rbx1 complex predicted an interaction between Ube2R1 residue 
Asp 102 and SCF subunit Rbx1 residue Arg 91 that was supported by functional binding 
experiments. Finally, acidic loop residues Glu 108 and Glu 112 are not in proximity of acceptor 
ubiquitin in nearly all of the models that were generated. In summary, these results are most 
consistent with a model where SCF controls the conformation of the Ube2R1/2 acidic loop 
which may serve to optimize stabilizing interactions between residues Glu 108 and Glu 112 and 
the donor ubiquitin. One notable exception may be Asp 103, where some of the models predicted 
an interaction between this residue and acceptor ubiquitin, a result that is consistent with 
previous protein cross-linking experiments (Chong et al., 2014).   
 While this work provides the most detailed molecular insight into the mechanism of 
Ube2R1/2 and SCF function to date, there are still many questions that need to be addressed. For 
instance, the modeling effort here suggests that the Ube2R1/2 acidic loop can adopt many 
different conformations, and it is possible that multiple conformations may exist during 
Ube2R1/2 function (potentially explaining how both Glu 108 and Glu 112 may simultaneously 
participate in catalysis by interacting with donor ubiquitin). Another topic of interest involves an 
essential step during catalysis, the deprotonation of Lys 48 on acceptor ubiquitin. We had 
previously speculated that a conserved histidine (His 98 in Ube2R1/2) may participate in 
deprotonation (Ziemba et al., 2013). While our models show that His 98 is in proximity to Lys 
48 on acceptor ubiquitin and may therefore play some role in lysine activation, it is likely that the 
mechanism also involves Ube2R1/2 residue Ser 138 which is structurally equivalent to an 
77 
 
aspartic acid residue present in most E2s that has been shown to be critical in promoting lysine 
deprotonation on the substrate (Yunus et al., 2006).  
 Collectively these studies demonstrate the effectiveness of using computational tools to 
gain structural insights into transient protein complexes as well as flexible regions within those 
structures. Using an iterative procedure of computational modeling and biochemical experiments 
that distinguish between theoretical models, the refinement of the initial models based on the 
experimental results provides a glimpse into protein function that may be inaccessible through 
more traditional structural biology methodologies. We believe that these procedures can be 
generally applied to a number of other protein complexes for which traditional methodologies 
have proved difficult or intractable.  
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ROBUST CULLIN-RING LIGASE FUNCTION IS ESTABLISHED BY A MULTIPLICITY 
OF POLY-UBIQUITYLATION PATHWAYS3 
4.1 Abstract 
 SCF ubiquitin ligases ubiquitylate and promote the degradation of hundreds of proteins, 
many of which are implicated in human disease. Human SCFs function with the ubiquitin-
conjugating enzymes (E2s) UBE2D1-4, UBE2R1 and UBE2R2, as well as the ubiquitin ligase 
ARIH1 but it is not known how these enzyme activities converge to enable SCF function. We 
used quantitative in vitro enzyme assays to show that UBE2D3 exhibits preference for the 
identity of the SCF substrate and/or receptor, that UBE2R2 provides only weak ubiquitylation 
activity at physiological concentrations, and that combinations of UBE2D3 or ARIH1 with 
UBE2R1/2 can effectively promote substrate poly-ubiquitylation, even at low concentrations. 
Surprisingly, despite the exceptional conservation of UBE2R1/2 across all eukaryotic organisms, 
ablation of both UBE2R1/2 had no effect on the stability of SCF substrates. A genome-wide 
CRISPR screen revealed that UBE2G1 buffers against the deletion of UBE2R1/2. UBE2G1 had 
robust in vitro activity with SCF, and its co-ablation with UBE2R1/2 in cells resulted in 
stabilization of the SCF substrate p27 as well as the Cul3-RING ligase substrate Nrf2. The 
results reveal the human SCF enzyme system is heavily buffered and suggest that SCF 
specificity is diversified by association with multiple catalytic enzyme partners.   
                                                          
3 This chapter was adapted from a manuscript under review at Elife: 
Hill S., Reichermeier K., Scott D. C., Samentar L., Coulombe-Huntington J., Izzi L., Tang X., 
Xiaojing T., Ibarra R., Bertomeu T., Moradian A., Sweredoski M. J., Caberoy N., Schulman B. 
A., Sicheri F., Tyers M., Kleiger G. (2019). Robust cullin-RING ligase function is established by 




 In the ubiquitin-proteasome system, ubiquitin ligases (E3s) bind to specific protein 
substrates to direct poly-ubiquitin chain formation and degradation by the 26S proteasome. There 
are at least 600 E3s in the mammalian proteome (Deshaies and Joazeiro, 2009), and alterations 
of the expression levels in several E3s or their substrates have been clinically and biochemically 
linked to cancer and other diseases in humans (Skaar, Pagan, & Pagano, 2014; Wang, Liu, 
Inuzaka, & Wei, 2014). E3s are modular enzymes that recruit both the protein substrate as well 
as a ubiquitin-conjugating enzyme (E2) bound to ubiquitin, a highly conserved 76 residue protein 
(Kleiger and Mayor, 2014). E3s promote the covalent modification of a lysine residue on the E3-
bound substrate, in most cases by direct transfer of the ubiquitin from E2 to substrate (Berndsen 
and Wolberger, 2014; Metzger, Pruneda, Klevit, & Weissman, 2014; Vittal et al., 2015).  
Ubiquitin contains 7 lysine residues, and the conjugation of any of these from substrate 
bound ubiquitin to an additional ubiquitin results in the formation of a poly-ubiquitin chain 
(Komander and Rape, 2012; Yau and Rape, 2016). A chain containing at least 4 ubiquitins is 
typically considered minimal for recognition by the 26S proteasome (Chau et al., 1989; Thrower, 
Hoffman, Rechsteiner, & Pickart, 2000), although two notable exceptions have been discovered. 
First, when multi-mono-ubiquitylated proteins become modified with chains containing less than 
4 ubiquitins, they may nevertheless be even better substrates of the proteasome than those 
modified with longer poly-ubiquitin chains at a single lysine (Lu, Lee, King, Finley, & 
Kirschner, 2015). Second, relatively small proteins that contain shorter poly-ubiquitin chains 
may also be recognized by the proteasome (Shabek et al., 2012).  
 Cullin-RING ligases (CRLs) are the largest family of E3s in the human proteome. CRLs 
are modular multi-subunit complexes that all contain a common core of a cullin subunit and a 
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‘really interesting new gene’ (RING) domain subunit (Harper and Tan, 2012; Lydeard, 
Schulman, & Harper, 2013; Zimmerman, Schulman, & Zheng, 2010). The cullin subunit acts as 
a scaffold for the CRLs, where the C-terminal segment binds to the RING subunit which recruits 
the E2-ubiquitin complex. The N-terminal cullin segment binds to adaptor proteins that recruit 
substrate receptors. The archetypal CRLs, named Skp1-cullin-Fbox (SCF) ligases, all contain the 
cullin subunit Cul1, the RING domain subunit Rbx1, and the adapter Skp1 that binds to both 
Cul1 as well as the substrate receptors called Fbox proteins (Petroski and Deshaies, 2005). The 
human genome encodes approximately 70 Fbox proteins (Lee et al., 2011). The presence of 
additional substrate receptors that interact with culllin subunits other than Cul1 collectively result 
in at least 200 CRLs in humans.  
 Genetic and biochemical studies suggested that in the budding yeast Saccharomyces 
cerevisiae the E2 enzyme Cdc34 is dedicated to SCF ligases (Feldman et al., 1997; Schwob, 
Bohm, Mendenhall, & Nasmyth, 1994; Skowyra et al., 1997). Whereas the yeast E2s Ubc4/5 do 
not support SCF activity in vitro, several reconstituted human SCF ubiquitylation reactions have 
been reconstituted with the human E2 orthologs Ube2D1-4 (Sakata et al., 2007; Wu et al., 2003; 
Wu et al., 2000). A “hand-off” model has been proposed for the SCFβTrCP substrate IΚBα, in 
which UBE2D3 transfers the first ubiquitin to a SCF-bound substrate (termed priming), and 
poly-ubiquitin chain elongation is catalyzed by the human Cdc34 ortholog UBE2R1 or its highly 
similar isoform UBE2R2 (Wu et al., 2010). More recently it was discovered that the E3 enzyme 
ARIH1 has potent priming activity in vitro for several human SCF complexes, that ARIH1 
interacts with at least 44 CRL substrate receptors in tissue culture cells, and that ARIH1 ablation 
results in the accumulation of several CRL substrates in vivo (Scott et al., 2016). Similar findings 
were also reported in Caenorhabditis elegans (Dove et al., 2017). Despite the apparent 
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requirement for UBE2D1-4 or ARIH1 to initiate a poly-ubiquitin chain on substrates, both 
Cdc34 and UBE2R1/2 are capable of priming as well as poly-ubiquitin chain extension in in 
vitro ubiquitylation assays (Kleiger et al., 2009b; Pierce et al., 2009; Saha and Deshaies, 2008). 
The relative contributions of these various mechanisms to SCF-mediated poly-ubiquitin chain 
formation on substrates have yet to be elucidated. 
 In this study, we used in vitro reconstitution of enzyme activities and genetic analysis of 
enzyme function in cells to explore the contributions of different SCF associated enzymes to 
SCF-mediated substrate ubiquitylation. Our results suggest the human CRL enzyme system is 
highly redundant and that this plasticity allows regulatory diversification of SCF function across 
a breadth of substrates.  
4.3 Results 
4.3.1 Intracellular concentrations of SCF-associated enzymes.  
We sought to resolve how multiple ubiquitin priming and poly-ubiquitin elongating 
enzymes collaborate with SCF ubiquitin ligases by measuring the individual rates of poly-
ubiquitin chain priming and elongation using pre-steady state kinetic measurements with 
different combinations of SCF-associated enzymes. To accomplish this goal, we compared the 
activities of two well-characterized and biologically important SCF ligases based on the βTrCP 
substrate receptor (SCFβTrCP) and the Fbw7 substrate receptor (SCFFbw7). SCFβTrCP was chosen 
because full-length βTrCP forms dimers, which has been shown to be important for ubiquitin 
ligase activity (Tang et al., 2007), and the SCFβTrCP complex can be produced in quantities that 
are sufficient for kinetic studies. SCFFbw7 lacking its dimerization domain was chosen since it can 
also be produced at high levels and because it has previously been shown that high affinity 
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substrates are ubiquitylated with similar efficiencies by dimeric or monomeric SCF complexes 
(Tang et al., 2007; Welcker et al., 2013), an observation that we also reproduced here (Figure 
4S.1). To simplify kinetic modeling of the ubiquitylation reaction, both complexes were assayed 
with peptide substrates acetylated at their N-termini and containing a single lysine acceptor 
residue.   
A critical parameter for measurement of the kinetics of in vitro reconstituted reactions is 
the concentrations for both ubiquitin chain initiator and elongator E2s and E3s needed to saturate 
the E3–substrate complex and thereby promote maximal rates of ubiquitin transfer to the 
substrate. Multi-turnover Michaelis-Menten kinetic assays were used to determine the levels of 
ARIH1, UBE2D3 and UBE2R2 necessary to saturate either SCFβTrCP or SCFFbw7 complexes 
(Figures 4S.2, 4S.3 and Table 4S.2).  
 A potential caveat with saturating kinetics is that E2 and E3 concentrations in cells may 
be insufficient to saturate the E3–substrate complex, resulting in slower rates of ubiquitin 
transfer to the substrate in vivo. To address this issue, single reaction monitoring (SRM) mass 
spectrometry was used to determine the copy numbers of ARIH1, UBE2D1-4, UBE2R1-2, as 
well as the SCF subunits CUL1 and SKP1 in several common tissue culture cell lines, enabling 
calculation of the protein concentration within the cell (Table 4S.1). To account for modest 
nuclear enrichment previously shown for UBE2R1 (Kleiger et al., 2009a), the activities of 






4.3.2 CRL partner reactions with SCF at physiological enzyme concentrations 
The rates of ARIH1-catalyzed ubiquitin chain initiation and elongation were obtained by 
measuring the pre-steady state kinetics of a single encounter ubiquitylation reaction containing 
SCFFbw7, single lysine Cyclin E peptide, and 2.5 µM ARIH1 to saturate the SCF–substrate 
complex (Figure 4.1A-C). The rate of chain initiation was 0.5 sec-1, the second ubiquitin transfer 
to substrate was only modestly slower (0.2 sec-1), and the rate of the third ubiquitin transfer was 
0.1 sec-1 (Table 4S.3). The kinetics were sufficient to generate products containing up to four 
ubiquitins on the substrate modified poly-ubiquitin chain prior to substrate dissociation from 
SCF (Figures 4.1B, 4.2A).  
 Reducing the concentration of ARIH1 some 7-fold lower to more physiological levels 
resulted in only modest changes to the rates of ubiquitin transfer. The rates of the first and the 
second ubiquitin transfers (0.2 sec-1 and 0.1 sec-1, respectively) were only 2-fold slower than in 
the case where ARIH1 was saturating for SCF, and the rates of the third ubiqiuitin transfers were 
within experimental error (Table 4S.3). As such, these reactions at lower ARIH1 levels still 





Figure 4.1 ARIH1 under single-encounter conditions. ARIH1 is capable of generating modest 
poly-ubiquitin chains onto SCF-bound substrate at either saturating or more physiological 
concentrations. (a) typical conditions for the single-encounter quench flow ubiquitylation 
reactions used to estimate the rates of ubiquitin transfer (also see Table S3). (b) autoradiogram of 
a Cyclin E ubiquitylation reaction with ARIH1 levels (2.5 μM) sufficient to saturate the SCF 
complex, where S0 represents unmodified substrate, S1 represents substrate modified with one 
ubiquitin, etc. (c) Data points and fit to the kinetic model of the reaction in (b) for substrate (S0) 
and two products (S1 and S2). Each data point represents the mean value from at least two 
independent measurements. (d) same as (b), except more physiological ARIH1 levels (Table 




Assaying ARIH1 with β-Catenin peptide substrate and SCFβTrCP resulted in both similar 
kinetics as well as ubiquitylated products compared with the reactions with Cyclin E peptide and 
SCFFbw7 (Figures 4.2B, 3B, and Table 4S.3). The rates of chain initiation were only 2-fold slower 
when the ARIH1 concentration was 2.5 µM or 0.36 µM (0.2 sec-1 and 0.1 sec-1, respectively), 
and the rates of the second ubiquitin transfers were comparable to those for Cyclin E. Taken 
together, these results demonstrate that ARIH1 rapidly initiates a poly-ubiquitin chain on SCF-
bound substrates and is capable of modest chain extension prior to product dissociation, even at 




Figure 4.2 ARIH1 has similar activities with other substrate receptor – substrate pairs. (a) Same 
as Figure 4.1B, except with β-Catenin peptide substrate and SCFβTrCP. (b), same as (a) except 
with more physiological ARIH1 levels 
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The rates of chain initiation and elongation were measured next for UBE2D3. At a 
saturating concentration of 10 µM, the rate of chain initiation was 0.1 sec-1 for SCFFbw7 and 
Cyclin E peptide (Figures 4S.4 and Table 4S.3), 5-fold slower than the same rate catalyzed by 
ARIH1. Similar to ARIH1, this rate was only reduced 2-fold when UBE2D3 levels were lowered 
to 3.7 µM to more accurately reflect cellular levels (Figures 4S.4 and Table 4S.1). However, 
when 10 µM UBE2D3 was assayed with β-Catenin peptide and SCFβTrCP, the rate of chain 
initiation (5 sec-1) was far more rapid than with Cyclin E peptide and SCFFbw7 (Figures 4S.5 and 
Table 4S.3). Reduction of the concentration of UBE2D3 by approximately 3-fold to 
physiological levels had only a negligible effect on the rate of chain initiation (Figures 4S.5 and 
Table 4S.3). With chain elongation rates between 0.2 sec-1 – 0.5 sec-1, UBE2D3 was also capable 
of substantial poly-ubiquitin chain assembly onto β-Catenin substrate, even at reduced levels 
(Figure 4.3B). Thus, in contrast with ARIH1, UBE2D3 activity is sensitive to either the identity 





Figure 4.3 Single-encounter substrate modification with various CRL partner combinations. Both 
ARIH1 and UBE2D3 are capable of poly-ubiquitin chain initiation as well as modest chain 
elongation in a substrate specific manner. (a) quantitation of the fractions of Cyclin E substrate 
(S0) and all products from the final 10 second time-points from quench flow reactions. Solid bars 
represent levels for reactions where ARIH1, UBE2D3, and/or UBE2R2 were saturating for SCF; 
empty bars represent reactions containing the same enzymes at more physiological levels (Table 
4S.1). Notice that UBE2R2 is capable of generating substantial products with long poly-ubiquitin 
chains when saturating for SCFFbw7, but produces almost no product when UBE2R2 levels are 
more physiological. (b) same as in (a), except with β-Catenin peptide substrate and SCFβTrCP.   
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When saturating levels (10 µM) of the ubiquitin-conjugating enzyme UBE2R1/2 were 
assayed with both SCFFbw7 and Cyclin E peptide or with SCFβTrCP with β-Catenin peptide, the 
rates of chain initiation were highly similar (0.1 sec-1 - 0.2 sec-1, respectively) and comparable to 
the rates generated by ARIH1 (Figures 4S.6, 4S.7, and Table 4S.3). Consistent with prior results, 
the rate of the second ubiquitin transfer was far more rapid for both substrates and SCF 
complexes (40 sec-1 and 30 sec-1 to mono-ubiquitylated Cyclin E and β-Catenin peptides, 
respectively).  The rates of the third ubiquitin transfers to SCF-bound substrates were also rapid, 
resulting in very long poly-ubiquitin chains on products (Figure 4.2), a hallmark of UBE2R1/2-
catalyzed ubiquitylation reactions. 
While reactions containing saturating UBE2R2 for SCF added impressively long poly-
ubiquitin chains onto substrate, reduction of the UBE2R2 levels by 20-fold to mimic cellular 
conditions resulted in the near elimination of any product for both Cyclin E and β-Catenin 
peptide (Figure 4S.7). Indeed, product levels were so low that we were unable to estimate the 
rate of poly-ubiquitin chain initiation for either substrate. This result strongly suggested that 
UBE2R1/2 are incapable of mediating substrate ubiquitylation in vivo without the assistance of 
other SCF-associated enzymes. 
We then compared the rates of chain initiation and elongation for reactions containing 
initiator E2 or E3 in combination with UBE2R2. Ubiquitylation reactions containing both 
saturating ARIH1 (2.5 µM) and UBE2R2 (10 µM) for SCFFbw7 were performed in the presence 
of Cyclin E peptide (Figures 4S.8). While the rate of chain initiation was only 2-fold slower than 
in comparison with the same reaction containing only ARIH1 (Table 4S.3), the rate of the second 
ubiquitin transfer to substrate was more than 10-fold slower than reactions containing UBE2R2 
alone (3 sec-1 versus 40 sec-1, respectively). Reduction of both ARIH1 (0.36 µM) and UBE2R2 
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(0.5 µM) to more physiological levels did not affect the rate of chain initiation, but the rate of 
chain elongation was further reduced compared to the reaction where these components were 
saturating for SCF (Figures 4S.8 and Table 4S.3). Nevertheless, the rates of chain elongation for 
ARIH1 in the presence of UBE2R2 were significantly faster than for reactions containing 
ARIH1 alone, resulting in substrates modified with poly-ubiquitin chains that were substantially 
longer than those formed by ARIH1 in the absence of UBE2R2 (Figure 4.3). Similar trends in 
the rates as well as the effects on poly-ubiquitin chains lengths were observed for β-Catenin 
peptide and SCFβTrCP (Figures 4S.9 and Table 4S.3). These results suggest that while ARIH1 can 
provide the initiator ubiquitin for subsequent elongation by UBE2R1/2, it also acts as a 
competitor for the elongation cycles in in vitro ubiquitylated reactions.   
The rates of chain initiation and elongation were then determined for analogous reactions 
containing both 10 µM UBE2D3 and UBE2R2 (Figures 4S.10, 4S.11, and Table 4S.3). While 
the rates of ubiquitin chain initiation were comparable to those from reactions containing 
UBE2D3 alone, the rates of the second ubiquitin transfer to substrate were suppressed compared 
to reactions containing UBE2R2 alone, in particular for reactions with β-Catenin peptide and 
SCFβTrCP (0.9 sec-1 versus 30 sec-1, respectively). Reduction of the levels of both UBE2D3 (3.7 
µM) and UBE2R2 (0.5 µM) further slowed the rates of chain elongation; however, long poly-
ubiquitin chains were still observed on substrates, especially β-Catenin peptide (Figure 4.3). 
These results suggested that, like ARIH1, UBE2D3 also acts as a competitor for chain elongation 
by UBE2R1/2.  
Considering that the average estimated physiological concentrations for ARIH1, 
UBE2D3, and UBE2R1/2 (Table 4S.1) were all quite close to the KM values of these enzymes for 
SCF (Table 4S.2), we reasoned that relatively subtle changes in ARIH1, UBE2D3, and 
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UBE2R1/2 levels may result in substantial differences in both the fraction of substrate converted 
into ubiquitylated product as well as the lengths of the poly-ubiquitin chains. To test for this, 
single encounter ubiquitylation reactions were assembled with SCFFbw7, Cyclin E peptide, and 
where ARIH1, UBE2D3, and UBE2R2 levels were assayed either up to 4 times higher or lower 
than their estimated physiological concentrations.  
 Very little product was observed for any of the reactions when the enzyme levels were 
assayed at either one-fourth or one-half the estimated cellular concentrations (Figure 4.4). 
Substantial mono-ubiquitylation of Cyclin E peptide occurred for both ARIH1 and UBE2D3 
when assayed at the estimated physiological concentrations, and introduction of UBE2R2 to 
these reactions also resulted in the formation of poly-ubiquitin chains onto product containing 4 
or more ubiquitins (Figure 4.4 and Figure 4S.12). Increasing ARIH1 levels to either twice or four 
times the estimated cellular concentration resulted in both increased conversion of substrate to 
product containing at least one ubiquitin, as well as substantial poly-ubiquitin chains on product 
(up to 5 ubiquitins in the latter case). Increasing UBE2D3 levels also resulted in greater product 
formation, although to a lesser extent than for ARIH1. The UBE2D3 product was also primarily 
mono-ubiquitylated. Increasing the UBE2R2 concentration also led to some product formation, 
all containing very long poly-ubiquitin chains. Finally, combining either ARIH1 or UBE2D3 
with UBE2R2 and assaying at levels two or four times greater than the estimated physiological 
levels resulted in greater amounts of product containing much longer poly-ubiquitin chains. 
Thus, subtle changes in the concentrations of ARIH1, UBE2D3, and UBE2R2 led to significant 
changes in both the amount of substrate converted to product as well as the lengths of the poly-




4.3.3 UBE2R1/2 is non-essential for degradation of known SCF substrates 
Since modest changes in enzyme levels, particularly UBE2R2, resulted in substantial 
changes in poly-ubiquitin chains appended to substrate, we reasoned that a 2-fold reduction in 
UBE2R1/2 levels might result in the stabilization of SCF substrates in the cell. Surprisingly, the 




Figure 4.4 Dilution series of CRL partner activities at cellular concentrations. Minor changes to 
the ARIH1, UBE2D3, and/or UBE2R2 levels result in substantial differences in both the fraction 
of substrate converted to product as well as the average number of ubiquitins in poly-ubiquitin 
chains. Single-encounter ubiquitylation reactions were initiated with either ARIH1, UBE2D3, 
UBE2R2, or combinations of either ARIH1 and UBE2R2 or UBE2D3 and UBE2R2 at levels 
determined from SRM mass spectrometry (middle panel; Table 4S.1). The same reactions were 
also performed with either a 2- or 4-fold reduction in the enzyme levels (left panel), or 2- or 4-




in either wild-type (WT) or UBE2R1 knock out HEK293T Flp-In T-Rex (293T-FiTx 
cells; Figure 4.5A). Note that ablation of UBE2R1 protein did not significantly affect UBE2R2 
mRNA levels, ruling out a dosage compensation effect (Figure 4S.13A). The rates of degradation 
of the SCFβTrCP substrate IΚBα were also comparable (Figure 4.5B), demonstrating that the 
ubiquitylation and degradation of these substrates is insensitive to the presence of UBE2R1 
protein. 
 Since the above results may be reconciled by the presence of UBE2R2 protein that may 
compensate for loss of UBE2R1 protein, UBE2R1/2 co-depletion was accomplished by siRNA-
mediated knockdown of UBE2R2 protein in both WT and UBE2R1 knock out 293T-FiTx cells. 
Transfection of UBE2R2-targeting siRNA into either WT or UBE2R1 knock out 293T-FiTx cells 
resulted in 90 – 95 % depletion of UBE2R2 mRNA without any effect on UBE2R1 mRNA levels 
(Figure 4S.13B) and markedly reduced UBE2R2 protein levels. The steady state levels of three 
SCF substrates, p27, Cyclin E, and β-Catenin, were unaffected by the absence of UBE2R1 
protein and knockdown of UBE2R2 protein levels. Furthermore, UBE2R1/2 depletion had no 
effect on either UBE2D3 or ARIH1 protein levels (Figure 4.5C). Degradation of IΚBα was also 
comparable between WT and UBE2R1/2 ablated cells (Figure 4.5D). Consistent with these 
results, cell cycle analysis demonstrated that UBE2R1/2 ablated cells had a similar cell cycle 




Figure 4.5 Reduction of UBE2R1/2 protein does not affect stabilities of four SCF substrates. (a) 
cyloheximide (CHX) chase time courses using either a WT or a UBE2R1 knock out 293T-FiTx 
cell line demonstrates that the SCFFbw7 substrates p27 and Cyclin E have similar stabilities in the 
presence or absence of UBE2R1. (b) TNF-induced degradation of IΚBα is comparable in either 
WT or UBE2R1 knockout cells. (c) Comparison of the steady state stabilities of β-CATENIN, 
p27, and CYCLIN E in either WT 293T-FiTx cells or UBE2R1 knock out cells treated with 
either control or siRNA targeting UBE2R2. The stabilities of the substrates as well as UBE2D3 
and ARIH1 proteins are comparable in all cases. (d) same as in (b), except with either WT or 
UBE2R1 knock out 293T-FiTx cells treated with either control or siRNA targeting UBE2R2. 
 
 
 While the above results strongly suggested that UBE2R1/2 protein is dispensable for the 
degradation of at least four key SCF substrates, it was possible that the remaining UBE2R2 
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protein from incomplete knockdown by siRNA treatment was sufficient to degrade these 
proteins. To address this, CRISPR-Cas9 technology was used to disrupt both UBE2R1 and 
UBE2R2 loci in HEK 293T cells. Multiple clones were isolated that contained frameshift indels 
that caused total ablation of UBE2R1 or UBE2R2 protein, as demonstrated by Western blotting 
with antibodies with high specificity to either UBE2R1 or UBE2R2 (Figure 4S.14A). 
Cycloheximide chase analysis performed on the UBE2R1/2 double knockout cell again 
demonstrated that p27 protein degradation rates were indistinguishable from control cells (Figure 
4S.14B). These results demonstrate that both UBE2R1 and UBE2R2 are entirely dispensable for 
the degradation of at least some SCF substrates.  
4.3.4 UBE2G1 functions redundantly with UBE2R1/2 
To explain how p27, Cyclin E, β-Catenin, and IΚBα become ubiquitylated in the absence 
of UBE2R1/2, we considered two potential hypotheses: (1) ARIH1 and/or UBE2D1-4 are 
sufficient for both initiation as well as modest poly-ubiquitin chain elongation (as evidenced by 
the kinetic results here); and (2) a different E2 may complement UBE2R1/2 activity in the cell. 
The first hypothesis predicts that ARIH1 and/or UBE2D1-4 might become essential in the 
absence of UBE2R1/2, whereas the second hypothesis suggests that one or more other E2s may 
become essential in the absence of UBE2R1/2.  
To address this question in an unbiased manner, we performed genome-wide CRISPR 
knockout screens in the NALM-6 pre-B cell lymphoma line with the previously reported EKO 
sgRNA library (Bertomeu et al., 2018) to identify genes that exhibit synthetic lethality with the 
loss of UBE2R1 and/or UBE2R2. Cell populations were first transduced with individual sgRNAs 
targeting either UBE2R1, UBE2R2, or both UBE2R1 and UBE2R2, as well as the AAVS1 locus 
and a non-targeting control sgRNA (Figure 4.6, 4.7, 4S.15). Each population was transduced 
100 
 
with the library pool and propagated for 14 days, followed by determination of sgRNA 
frequencies by next generation sequencing and generation of gene-level scores by the RANKS 
algorithm (Bertomeu et al., 2018).  Differential RANKS scores for every gene in each 
experimental screen were obtained by subtraction of the averaged RANKS scores of the two 
control screens. Strikingly, the UBE2G1 gene scored as the top synthetic lethal interactor in both 
replicates of the UBE2R1/2 double knockout screen but did not score in either of the UBE2R1 or 
UBE2R2 single knockout screens (Figures 4.7B-E). Moreover, out of the 5 experimental screens 
analyzed, the only statistically significant hit (FDR<0.05) was UBE2G1 in the UBE2R1/2 double 
knockout screen. We did not observe any other significant genetic interactions with loss of 




Figure 4.6 Design of a genome-wide CRISPR fitness screen. Schematic of CRISPR screen 





The three-way genetic interaction between UBE2R1, UBE2R2 and UBE2G1 was 
validated by population-level knockout of UBE2G1 in UBE2R1 and UBE2R2 single and double 
knockout clones in the NALM-6 parental cell line. Assessment of the frequency of colony 
formation in Matrigel medium confirmed that only the triple knockout combination had a defect 
in cell proliferation and viability (Figure 4S.16). These genetic screen data suggested that 
UBE2G1 uniquely buffers loss of UBE2R1/2, and in particular that the elongation activity of 
ARIH1 and UBE2D3 are unable to substitute for the three dedicated elongation E2 enzymes. 
To determine whether depletion of UBE2G1 may affect the stability of SCF substrates, a 
UBE2R1/2 double knockout HEK 293T cell line was treated with siRNAs that targeted either 
UBE2G1 alone or in combination with UBE2G2. Indeed, p27 levels were stabilized upon 
depletion of UBE2G1 protein (Figure 4.8A), confirming the specific functional redundancy 
between UBE2R1/2 and UBE2G1. To determine whether our observation may be extended to 
additional CRLs, siRNA-mediated knockdown was performed in WT and UBE2R1 knockout 
293T-FiTx cell lines followed by assessment of substrate levels by Western blot. The CRL3Keap1 
substrate NRF2 was stabilized, but only when UBE2R1/2 and UBE2G1 had been collectively 








Figure 4.7 A genome-wide CRISPR fitness screen identifies UBE2G1.(b) Scatter plot of 
differential RANKS scores of all genes in replicate UBE2R1/2 double knockout screens. 
Negative values indicate sgRNA depletion relative to the control population background and 
positive values indicate sgRNA enrichment. (c,d). Scatter plot comparisons of differential 
RANKS scores for UBE2R1/2 double knockout compared to UBE2R2 and UBE2R1 screens. For 
both plots, UBE2R1/2 scores are the average of the two screens in panel b. (e) Scatter plot 
comparison of UBE2R1 versus UBE2R2 screens. Scores for UBE2R2 screens are the average of 





Figure 4.8 UBE2G1 functions in synergy with UBE2R1 and SCF in cells. (a) Comparison of the 
steady state stability of p27 protein in UBE2R1/2 double knockout HEK 293T cells treated with 
single or pooled siRNAs targeting either UBE2G1, UBE2G2, or both in combination. (b) 
Comparison of the steady state stability of Cul3Keap1 substrate Nrf2 in either WT or UBE2R1 
knock out 293T-FiTx cells treated with either control or with UBE2R2 and UBE2G1 siRNAs. (c) 
Autoradiogram of a Cyclin E ubiquitylation reaction with UBE2G1 levels (12.5 μM) sufficient to 
saturate the SCF complex, where S1 represents mono-ubiquitylated substrate, S2 represents 
substrate modified with two ubiquitins, etc. (d) Schematic showing how SCF-catalyzed substrate 
ubiquitylation occurs in yeast or human cells.  
 
 
 We then determined whether UBE2G1 can support SCF-mediated substrate 
ubiquitylation in vitro. UBE2G1 itself had no measurable chain initiation activity, but exhibited 
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substantial chain elongation activity against either mono-ubiquitylated β-Catenin or Cyclin E 
peptides in the presence of SCFFbw7 or SCFβTrCP, respectively (Figure 4S.17A).  The KM of 
UBE2G1 was estimated as 1.30 ± 0.2 μM from multi-turnover Michaelis-Menten kinetics in the 
presence of mono-ubiquitylated Cyclin E peptide substrate (Figures 4S.17B, C and Table 4S.2). 
The pre-steady state kinetics of UBE2G1-catalyzled ubiquitin transfer to the Cyclin E peptide 
yielded rates of ubiquitin transfer of 1 ± 0.1 sec-1 under conditions where UBE2G1 levels were 
sufficient to saturate SCF (Figure 4.8C and Figure 4S.17D; Table 4S.3). In terms of enzyme 
efficiency (kobs/Km), the UBE2R2 efficiency (1.3x108 M-1 sec-1) was some 173-fold greater than 
for UBE2G1 (7.7x105 M-1 sec-1) for the first ubiquitin transfer to mono-ubiquitylated substrate, 
and 17-fold greater for the subsequent transfer. Thus, while UBE2R2 is far more efficient during 
catalysis of ubiquitin transfer to substrate on SCF, UBE2G1 activity is nevertheless sufficient to 
poly-ubiquitylate substrates that have been primed by either UBE2D1-4 or ARIH1. Collectively, 
these results demonstrate that UBE2G1 can act as a dedicated elongation E2 for SCF complexes, 
and thereby buffer cells against the loss of UBE2R1 and UBE2R2.  
4.4 Discussion 
Our studies using in vitro enzyme kinetics and genetic approaches have uncovered new 
complexities in the mechanism of poly-ubiquitin chain initiation and elongation by human SCF 
ubiquitin ligases. First, comparison of the ARIH1- or UBE2D3-catalyzed ubiquitin chain 
initiation demonstrates that the rates are not substantially affected by enzyme concentrations that 
range from physiological to saturating levels. Second, while the rates of ubiquitin chain initiation 
by UBE2R2 when saturating for SCF are comparable to those of ARIH1 and UBE2D3, at 
physiological levels UBE2R2 clearly cannot support ubiquitin chain initiation or ubiquitylated 
product formation. Third, the rate of chain initiation by UBE2D3 for β-Catenin peptide and 
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SCFβTrCP is some 50-fold faster than for reactions containing SCFFbw7 and Cyclin E peptide, 
indicating that UBE2D3 has a strong preference for some substrates and/or substrate receptors. 
Fourth, although ARIH1 and UBE2D3 can promote modest chain elongation, saturating levels of 
UBE2R2 can extend chains at up to 200-fold faster rates. Fifth, the combination of either 
UBE2D3 or ARIH1 with UBE2R2 partially suppresses chain elongation by UBE2R2, suggesting 
competition between the initiating and elongating enzymes. Finally, UBE2R1/2 function is 
genetically buffered by UBE2G1, such that loss of UBE2R1/2 does not cause overt proliferation 
defects in cell line models, whereas the simultaneous loss of all three E2s leads to inviability. 
Consistently, UBE2G1 supports chain elongation activity against primed mono-ubiquitylated 
substrates in vitro.  
 Our results suggest that human SCF-catalyzed substrate ubiquitylation has evolved 
additional regulatory layers compared to the simpler yeast SCF system (Figure 4.8D). In S. 
cerevisiae, Cdc34 appears both necessary and sufficient for SCF function since Ubc4/5 (the 
UBE2D1-4 orthologs) have no in vitro activity with reconstituted yeast SCF and cannot 
compensate for the loss of CDC34 in cells. Furthermore, a functional equivalent of ARIH1 has 
not been identified in yeast. While it is surprising that Cdc34 homologs UBE2R1 and UBE2R2 
appear to be dispensable in human cell lines, this difference may in part be explained by the 
respective concentrations of Cdc34 and UBE2R1/2 in yeast versus human cells. The 
concentration of Cdc34 in the yeast nucleus has been estimated at approximately 10 µM and 2- 
to 3-fold lower in the cytoplasm (Kleiger et al., 2009a). Based on the kinetic results here, these 
levels would be sufficient for robust chain initiation and elongation. In contrast, UBE2R1/2 
protein levels in several human cell lines are at least an order of magnitude lower than in yeast, 
and well-below the low micromolar value of the KM of UBE2R2 for SCF bound to an 
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unmodified substrate (Table 4S.2). On the other hand, the KM of UBE2R2 for SCF bound to a 
mono-ubiquitylated substrate is approximately 0.3 µM, similar to the physiological concentration 
of UBE2R1/2 in tissue culture cells, thus explaining why UBE2R1/2 is still able to promote 
chain elongation on primed substrate in vitro.  
 A possible exception to this interpretation may be our observation that a fraction of 
UBE2R1 is concentrated into foci in which protein levels may be higher (Figure 4S.18A), and 
thus potentially capable of initiating localized ubiquitylation reactions with CRL ligases. 
Multiple E3s contain sequence motifs that may drive the formation of membraneless organelles 
such as nuclear speckles and Cajal bodies (Hughes et al., 2018). In particular, the Cul3 substrate 
receptor SPOP forms such structures in cells in the presence of its substrates (Bouchard et al., 
2018). Additional experiments are necessary to determine whether SCF or other CRLs and their 
substrates are co-located within UBE2R1 foci, and whether UBE2R2 or UBE2G1 also form foci. 
 Our genome-wide genetic screen suggests that CRL function is more buffered in human 
cells compared to yeast. Aside from UBE2G1, at least at the level of resolution of our screen, we 
detected no other significant genetic interactions with loss of UBE2R1/2, including ARIH1 and 
UBE2D3. This result implies that the elongation activity of ARIH1 and UBE2D3 are insufficient 
to compensate for the combined loss of UBE2R1/2 and UBE2G1. In contrast, conditional alleles 
of CDC34 exhibit many dozens of well-documented synthetic lethal interactions in yeast 
(Oughtred et al., 2019). We note that while the UBE2R1/2 double mutant is viable in two 
different transformed cell lines, UBE2R1/2 function may still be essential in an organismal 
context, an issue that remains to be addressed.  
 Why did SCF-catalyzed substrate ubiquitylation evolve separate chain initiating versus 
elongating enzymes, and why are multiple initiators and elongating E2s necessary? One likely 
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reason is that this separation of function affords additional opportunities to diversify the control 
of SCF ligase activity. For instance, since ARIH1 is active only in the presence of neddylated 
CRL complexes, and SCF complexes tend to be activated only when bound to substrate 
(Emberley, Mosadeghi, & Deshaies, 2012; Enchev et al., 2012; Fischer et al., 2011; Pierce et al., 
2013), ARIH1 activity is held in check unless it is in the presence of activated SCFs. At least in 
vitro, saturating levels of UBE2R1/2 have substantial activity with un-neddylated SCF, such that 
the ARIH1-catalyzed hand-off mechanism may prevent unwanted auto-ubiquitylation of E3s not 
bound to substrate. A further layer of control appears to lie at the poly-ubiquitin chain initiation 
step, based on E2 specificity for particular substrates and/or substrate receptors. Thus, while 
UBE2D3 was less efficient than ARIH1 at chain initiation onto Cyclin E peptide substrate, the 
rate of the first ubiquitin transfer to β-Catenin peptide (5 sec-1) was 50-fold greater than with 
Cyclin E peptide, and 25-fold faster than ARIH1 for the same reaction. This effect may be 
explained by the affinity of the E2-E3 interaction and competition between different initiating 
enzymes. For instance, we observed that the KM of UBE2D3 for SCFFbw7 is significantly higher 
than for SCFβTrCP. Similarly, ARIH1 but not UBE2D3 supports in vitro ubiquitylation of CRY1 
bound to SCFFbxL3 (Scott et al., 2016). The use of multiple E2s and initiating enzymes evidently 
allows additional functional diversification across the SCF substrate repertoire.  
 The slower ubiquitin transfer rate of UBE2G1 compared to UBE2R1/2, and the weak 
elongation activity of ARIH1 and UBE2D3 may have biological relevance. For instance, delayed 
substrate ubiquitylation and degradation is important during mitotic exit in yeast (Rape, Reddy, 
& Kirshner, 2006) and in addition the proteasome is capable of recognizing substrates modified 
by different chain lengths and/or on different lysine residues (Lu et al., 2015). Whether such 
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effects are important for UBE2G1-mediated degradation of particular CRL substrates remains to 
be determined.  
Many other details remain to be elucidated regarding how SCF and other CRLs function 
with a suite of ubiquitin-modifying enzymes. Do different combinations of ARIH1 or UBE2D3 
with UBE2R1/2 or UBE2G1 produce different products that alter the kinetics of substrate 
degradation? What is the structural basis that underpins initiation versus elongation activities? 
How do the localized dynamics of E2, ARIH1 and SCF interactions in vivo relate to function? 
Are there yet additional E2s or E3s that can also function with CRLs under different 
circumstances? Answers to these questions will further our understanding of this important and 
fascinating enzyme system. 
Finally, the combinatorial plasticity of SCF chain initiation and elongation reactions may 
have important practical considerations in drug discovery. Recently, bivalent small molecule 
ligands have been developed to target non-cognate substrates to E3 enzymes, and thereby 
eliminate proteins that contribute to tumorigenesis and other disease states (Paiva and Crews, 
2019). This promising E3-based therapeutic approach, termed event-driven pharmacology (Lai 
and Crews, 2017), will be enabled by a more precise understanding of E3 catalytic mechanisms 
(Scudellari, 2019). To date, such "molecular glue" ligands have been developed for several CRL 
complexes including scaffolds that direct neo-substrates to the CUL4CRBN, CUL4DCAF15, 
CUL2VHL and CUL3KEAP1 enzymes (Paiva and Crews, 2019). It seems likely that particular 
combinations of chain initiating and elongating enzymes will preferentially modify neo-
substrates in a context-specific fashion.  For example, UBE2G1 has recently been shown to 
mediate chain elongation of neomorphic substrates that are bridged to CRL4CRBN by thalidomide 
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5.1 Conclusions and summary of findings 
Through refined assays, it was uncovered that different CRL partners demonstrate 
variable activities in response to storage conditions. An established enzyme titration 
experiment to measure Michaelis-Menten parameters of Cdc34 showed that the E2’s 
affinity for SCF is decreased 4-fold by multiple freeze-thaw cycles at 1 mM compared to 
a single freeze-that cycle at 100 μM. In addition, performing reactions with Cdc34 where 
added ddH2O constituted only 40% of the final reaction resulted in a 3-fold loss in SCF 
affinity relative to reactions containing 55% added ddH2O. Despite Cdc34’s sensitivity, 
UbcH5 was shown to be relatively resistant to such experimental conditions. Ideally, E2s 
should be frozen for long-term storage while relatively dilute only once, and then be 
concentrated after the first thaw if needed, to avoid excess storage buffer in any final 
reaction. These findings would prove to be valuable for future studies directly comparing 
the activities of the E2s. 
The mechanism by which Cdc34 assembled ubiquitin chains in a lysine-48 
manner was previously only approximate to this study. To develop a molecular model of 
how Cdc34 positioned incoming acceptor ubiquitin to promote lysine-48 specificity, 
computational modelling was employed. A constraint between the acceptor ubiquitin 
lysine-48 and the Cdc34-donor ubiquitin active site thioester resulted in a dozen different 
clusters of potential models, all representing different rotations along the lysine 48-
cysteine axis (Figure 3.1). Several different charge-swap point-mutations at predicted 
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sites of Cdc34-ubiquitin binding were designed, and were recombinantly expressed in 
bacterial cells. 
Each mutant pair was validated through in vitro ubiquitylation kinetics assays, the 
hypothesis being that that while mutations on one side of the predicted Cdc34-ubiquitin 
interface would result in a defective catalytic rate, introducing complementary mutations 
at the opposite face would compensate the defect. To measure the activities 
quantitatively, the di-ubiquitin assay was utilized. The R54D ubiquitin mutant resulted in 
a 50-fold defect in catalytic activity, and was rescued within 3-fold of the wildtype 
activity upon assay with the D143K Cdc34 mutant (Figure 3.2). The D143K mutant was 
7-fold defective when assayed with wildtype ubiquitin, indicating that the Cdc34 
mutation didn’t simply cause hyperactivity (Figure 3.2). To demonstrate validity in an 
E3-dependent assay, a multiple substrate turnover ubiquitylation assay containing SCF 
and substrate peptide was used. This showed a qualitative rescue in ubiquitin chain 
lengths to wildtype levels with the R54D-D143K pair, relative to stunted chains of the 
R54D-wildtype pair (Figure 3.6). 
The mutant pair was consistent with one of the dozen models generated, and 
displayed a structure analogous to that of UBE2S, which had been previously-validated 
in the context of lysine-11 chain synthesis (Wickliffe et al., 2011). Knowledge of the 
Cdc34-ubiquitin interface then allowed for a second iteration of modeling, where the 
Cdc34-ubiquitin model would be fit to a number of different conformations with the SCF 
RING domain protein Rbx1. Many models suggested that one or more residues of 
Cdc34’s acidic loop directly engaged the E3 to form salt bridges (Figure 3.8). Further 
rounds of charge-swap mutations produced a Cdc34 D102K-Rbx1 R91E pair which 
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rescued a 15-fold defect in KM by 3-fold relative to Cdc34 wildtype-Rbx1 R91E pair, 
indicating a possible direct role for the acidic loop in SCF binding (Figures 3.9, 3.10). 
The multiple turnover assay used allows E3 substrates to associate and dissociate 
many times over a period of minutes or hours. This causes rate-limiting by the substrate 
dissociation rate, which obscures the individual rates of ubiquitin transfer, and does not 
accurately resemble ubiquitylation in the cell, where competing activities and a need for 
fast cellular response exists. A single-encounter quench flow assay was therefore used, 
such that the reaction is initiated by the mixture of pre-incubated radiolabeled 
substrate:SCF complex, and pre-incubated ubiquitin, E1, Cdc34, and 1000-fold excess 
unlabeled SCF. The substrate used was a mono-ubiquitylated β-catenin substrate peptide, 
which were ubiquitylated with either wildtype ubiquitin or with R54D ubiquitin. 
Assaying with D143K Cdc34 resulted in ubiquitin transfer rates between 0.7 sec-1 - 0.8 
sec-1 of ubiquitin transfer to the wildtype-ubiquitylated substrate, whereas much faster 
rates between 4 sec-1 and 11 sec-1 resulted from use of the R54D-ubiquitylated substrate, 
further validating the R54-D143 ion pair (Figure 3.7).  
Applying the quench flow assay to fully wildtype Cdc34 and ubiquitin revealed 
surprisingly rapid kinetics, with a slower initial ubiquitin transfer rate of 0.1 sec-1 – 0.2 
sec-1 for either substrate, followed by a rapid second ubiquitin rate of between 30 sec-1 – 
40 sec-1, and further chain extension steps between 4 sec-1 – 7 sec-1 (Table 4S.3). This 
revelation prompted a more in-depth study of the kinetics of SCF activity. The ARIH1 




All of the previous quench flow experiments were performed with Cdc34, 
UbcH5, or Arih1 at saturating concentrations several times above measured KM (Figures 
4.1, 4.2, 4S.4 – 4S.11, Table 4S.2). UbcH5 or Arih1 in absence of Cdc34 resulted first 
ubiquitin transfer steps of 5 sec-1 or 0.5 sec-1 for their respective ideal substrates of β-
catenin and cyclin E, whereas the presence of Cdc34 reduced these rates modestly to 4 
sec-1 or 0.2 sec-1, respectively (Table 4S.2). However, the presence of either initiator 
significantly impacted Cdc34’s second transfer rate to 0.9 sec-1 or 3 sec-1 for UbcH5 and 
Arih1, and the fraction of modified substrate containing four or more ubiquitins by use of 
initiator was at best 2-fold improved, and at worst 2-fold reduced (Table 4S.3). This 
suggested substantial amounts of competition between CRL partners for binding SCF’s 
Rbx1 at the concentrations used. 
Utilization of selected reaction monitoring revealed cellular concentrations of 
these CRL partners in four different cell lines, averaging 250 nM for Cdc34, 1.85 μM 
UbcH5, and 180 nM for Arih1, all substantially lower than the saturating 10 μM 
concentrations used for Cdc34 and UbcH5, and the 2.5 μM concentration used for Arih1 
(Table 4.1). A two- and four-fold titration series above and below the measured cellular 
concentrations revealed that substrate modification levels were highly sensitive around 
these concentrations (Figure 4.3). Fluorescent confocal microscopy of UBE2R1 revealed 
it to be substantially localized to the nucleus, and therefore the quench flow experiments 
were performed again at concentrations twice that of the cellular concentrations reported 
above (Figure 4S.18).  
Under conditions closer to those within the cell, support for the hand-off model 
became much stronger. Cdc34 was incapable of turning over significant amounts of 
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product over the time course, and it was not even possible to measure individual rates of 
ubiquitin transfer (Figure 4S.7). However, in the absence or presence of UBE2R2, 
UbcH5 and Arih1 still maintained initial transfer rates of 3 sec-1 or 0.2 sec-1 at cellular 
concentrations, and UBE2R2 maintained subsequent ubiquitin transfer rates between 3 
sec-1 and 7 sec-1 for either combination with initiator (Figures 4S.8, 4S.9, 4S.10, 4S.11). 
The hand-off model became more compelling under physiological conditions, with a 
substantial percentage of product containing four or more ubiquitins in the presence of 
both initiator and UBE2R2 (Figure 4.2). 
To test the hand-off model, total UBE2R1/2 levels were reduced by 
approximately 90% in HEK293T cells containing a homozyhous UBE2R1 deletion then 
followed by siRNA inhibition of UBE2R2 mRNA. Despite this, no substantial change in 
the stabilities of known SCF substrates was observed (Figure 4.4). UBE2R1/2 double-
deletion cells tested later revealed that in human cells, in contrast to S. cerevisiae, they 
are not essential genes, and that levels of the SCF substrate p27 were insensitive to the 
deletions by Western blotting (Figure 4S.14). 
A NALM-6 cell line was then subjected to CRISPR to target UBE2R1 and/or 
UBE2R2 specifically, followed by genome-wide sgRNA targeting. For cells featuring 
UBE2R1/2 knockout, synthetic lethality resulted only from the additional targeting of 
UBE2G1 (Figure 4.5). Further Western blotting of UBE2R1/2 double-deletion cells in the 
presence of anti-G1 siRNA resulted stabilization of p27 (Figure 4.6). UBE2G1 was 
further validated as a CRL partner upon reconstitution using mono-ubiquitylated cyclin E 




5.2 Future directions 
The discovery that UBE2G1 plays a role in SCF activity comparable to that of 
Cdc34 represents an exciting expansion of SCF chemistry. One immediate avenue of 
exploration is to uncover the molecular mechanism of UBE2G1 chemistry. From 
available crystal structures and molecular evolution studies, UBE2G1 follows the 
canonical E2 fold relatively closely, with only two obvious deviations from that fold. The 
first and better-explored feature is the presence of an acidic loop, something also found in 
UBE2G2 and UBE2R1/2, all four which are also known to be K48-specific E2s. The 
availability of another E2 to study provides a new angle from which to investigate at the 
mechanism, and potentially uncover new insights. Molecular modelling as described in 
Chapter 3 could be used on UBE2G1 to determine a new role for the acidic loop. 
The second unique motif of UBE2G1 is a 20 residue C-terminal tail. UBE2R1/2 
possesses a 100 residue long C-terminal tail, with the distal acidic portion facilitating 
rapid E2-E3 cycling, and the proximal portion possessing multiple ubiquitin binding 
sites, likely engaging the first acceptor ubiquitin to specify elongation. UBE2K, another 
lysine-48-specific E2, also possesses a C-terminal tail with the ability to engage ubiquitin 
directly (Merkley & Shaw, 2004). Even outside of lysine-48 ubiquitylation, other poly-
ubiquitin chain builders tend to be require additional insertions or extensions, e.g. the 
220-residue lysine-11-specific UBE2S (Wickliffe et al., 2011). While the compact 
UbcH5 family can catalyze specific chain linkages, it requires the context of certain E3 
complexes to do so, such as the Linear Ubiquitin Chain Assembly Complex (LUBAC) 
which turns UbcH5 into a strong linear ubiquitin chain builder (Stieglitz, Morris-Davies, 
Koliopoulos, Christodoulou, & Rittinger, 2012). However, SCF does not direct chain 
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specificity of UbcH5, and currently there is no obvious mechanism by which SCF could 
do so for UBE2G1.  
UBE2G1 may therefore represent a kind of minimal ubiquitin elongating enzyme, 
studies of which could have broad implications for lysine-48 chemistry in general. While 
D143 was identified as a critical residue for UBE2R1/2 lysine-specificity, which is 
conserved in UBE2G1, UBE2R1/2 also requires residues both in its proximal and distal 
tail in order to promote chain extension. UBE2G1 being highly-specific for ubiquitin-
modified substrates, yet having no measurable activity towards unmodified substrates, 
could be explained by this shortened tail. This is distinct from UBE2R1/2, which shows 
strong preference towards modified substrates, but is capable of initiation if the E2s are 
present in a sufficiently high concentration.  
However, an alternative possibility is that our model substrates are inadequate for 
UBE2G1 catalysis, or that UBE2R1/2’s tail is responsible for its faster rate of chain 
synthesis and its modestly lower KM. These hypotheses may all be tested relatively easily 
using SCF-dependent assays already described in the present work, after generating a 
variety of mutant constructs. For example, UBE2G1 tail truncations and mutations could 
quickly test whether or not its short tail is relevant at all to its activity. It is also plausible 
that the lengthy acidic tail of UBE2R1/2 provides the flexibility to reach short artificial 
peptides more easily, which UBE2G1 cannot. The question of substrate lysine 
accessibility upon E2-E3 binding is an ongoing one (Kamadurai et al, 2013).  
While the findings of Chapter 4 demonstrate that UBE2G1 serves a role of 
redundancy by buffering UBE2R1/2 activity, the results cannot exclude that the E2s may 
be differentiated in the context of particular ubiquitylation substrates. Cyclin E and β-
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catenin peptides, used for the kinetics assays to show shared activity between two 
different substrates and substrate receptors, ultimately represent only a tiny fraction of all 
possible ubiquitylation substrates. Because expressing, purifying, and validating 
substrates individually for use in in vitro experiments is laborious, a proteomics-based 
approach would add the most value. 
Experiments are currently underway to generate different combinations of CRL 
partner deletions using a CRISPR-Cas9 system, including ΔUBE2R2, ΔUBE2G1, and 
ΔUBE2R2/G1 strains. Ablation of UBE2G1 levels in ΔR1/R2 cells is lethal, and as a 
result we are also generating cell lines to reduce its levels inducibly. These cell lines 
could then be harvested and subjected to mass spectrometry for the purpose of identifying 
new substrates stabilized upon the near-elimination of all three CRL partners. 
UBE2G1 was first discovered as a partner of Cul4 in the context of treatment by 
lenalidomide inducing cereblon degradation, Cul4 being part of a CRL which had 
unestablished activity with UBE2R1/2 (Lu et al., 2018). Currently, it is ambiguous as to 
whether currently known CRL partners function with other cullins as they do with Cul1. 
Biochemical analyses of other CRLs following the same methodology of the present 
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Figure 3S.1 Single-turnover SCF reaction with single-mutant conditions. (A) Time course 
showing the step-wise transfer of R54D ubiquitin to SCF-bound substrate in the presence of WT 
Ube2R2. (B) Schematic showing the rates of ubiquitin transfer to substrate as well as the rates of 
substrate and product dissociation from SCF with WT Ube2R2 and R54D acceptor ubiquitin. (C) 
Graph plotting either the disappearance of mono-ubiquitylated substrate (above) or the 
appearance of di-ubiquitylated product (below) over time in the presence of WT Ube2R2. Error 








Figure 4S.1 Comparison of reactions containing full-length or Δdimer substrate receptor. 
Ubiquitylation reactions catalyzed by UBE2D3 (10 μM), UBE2R2 (10 μM), or ARIH1 (2.5 μM) 
in the presence of SCF and either full-length or Δdimer substrate receptor. Single encounter 
ubiquitylation reactions were carried out in the presence of 0.5 μM neddylated SCF and 0.1 μM 
32P-labeled Cyclin E peptide substrate. Reactions were quenched after 10 seconds with 2X SDS-




Figure 4S.2 Estimation of affinity for CRL partners with ARIH1 or UBE2D3. Estimating the KM 
of Arih1 or Ube2D3 for the β-Catenin and Cyclin E peptide substrates used in this study. (a) 
multi-turnover ubiquitylation reactions were assembled in the presence of constant amounts of 
SCFFbw7 and 32P-labeled Cyclin E peptide and increasing amounts of Arih1 protein. Each lane 
represents a single ubiquitylation reaction used to calculate the reaction velocity (see 
experimental conditions; Supplemental Table S3). (b) same as in (a), except with β-Catenin 
peptide substrate and SCFβTrCP. (c) The reaction velocities from the reactions in (a) and (b) were 
plotted as a function of the Arih1 protein concentration and the data were fit to the Michaelis-
Menten equation using nonlinear curve fitting (Prism 6). Each data point represents the mean of 
the reaction velocities measured at least in duplicate. (d) same as in (a), except with Ube2D3 







Figure 4S.3 Estimation of affinity for CRL partners with UBE2R2. Estimating the KM of 
Ube2R2 for the β-Catenin and Cyclin E peptide substrates used in this study. (a) same as in 
Figure 4S.2A, except with Ube2R2 protein and mono-ubiquitylated cyclin E peptide. (b) same as 
in Figure 4S.2B, except with Ube2R2 and mono-ubiquitylated β-Catenin peptide. (c) same as in 







Figure 4S.4 Single-encounter Ube2D3 reactions with Fbw7 and Cyclin E. Ube2D3 is capable of 
generating modest poly-ubiquitin chains onto SCF-bound substrate at either saturating or more 
physiological concentrations. (a) autoradiogram of a Cyclin E ubiquitylation reaction with 
Ube2D3 levels sufficient to saturate the SCF complex, where S0 represents unmodified 
substrate, S1 represents substrate modified with one ubiquitin, etc. (b) Data points and fit to the 
kinetic model of the reaction in (b) for substrate (S0) and mono-ubiquitylated product (S1). Each 
data point represents the mean value from at least two independent measurements. (c,d) same as 





Figure 4S.5 Single-encounter Ube2D3 reactions with βTrCP and β-Catenin. Ube2D3 is capable 
of generating modest poly-ubiquitin chains onto SCF-bound substrate at either saturating or more 
physiological concentrations. (a,b) same as Figures 4S.4A, B, except with β-Catenin peptide 







Figure 4S.6 Single-encounter Ube2R2 reactions with Fbw7 and Cyclin E. Ube2R2 generates 
robust poly-ubiquitin chains onto SCF-bound substrates, but only at levels sufficient to saturate 
SCF. (a) autoradiogram of a Cyclin E ubiquitylation reaction with saturating Ube2R2 levels, 
where S0 represents unmodified substrate and S1 represents substrate modified with one 
ubiquitin, etc. (b) Data points and fit to the kinetic model of the reaction in (b) for substrate (S0) 
and mono- and di ubiquitylated products (S1 and S2 respectively). Notice that S1 is barely 
detectible since it is very rapidly converted to S2. As such, estimation of the rate of ubiquitin 
transfer from S1 to S2 was done independently (see below). Each data point represents the mean 
value from at least two independent measurements. (c) Mono-ubiquitylated Cyclin E peptide 
(S1) was prepared and used in ubiquitylation reactions containing SCFFbw7 and the sameUbe2R2 
levels as in (a). Reactions were also carried out in the presence of lysine-less (K0) ubiquitin, such 
that only a single product (S2) is formed over the time-course. (d) Data points and fit to the 
single, exponential decay of S1 and the formation of S2. Notice how the conversion of S1 to S2 
is nearly completed after only 20 milliseconds. Data points represent the mean value from at 




Figure 4S.7 Single-encounter Ube2R2 reactions with βTrCP and β-Catenin. Ube2R2 generates 
robust poly-ubiquitin chains onto SCF-bound substrates, but only at levels sufficient to saturate 
SCF. (a,b) same as in Figures 4S.6A, B, except with β-Catenin peptide substrate and SCFβTrCP. 
(c,d) same as in Figures 4S.6C, D, except with mono-ubiquitylated β-Catenin peptide substrate 
and SCFβTrCP. (e) same as in Figure 4S.6A, except with more physiological Ube2R2 levels 
(Table S2). Notice how product formation is barely apparent even after 10 seconds. (f) same as 





Figure 4S.8 Single-encounter Ube2R2/Arih1 reactions with Fbw7 and Cyclin E. The 
combination of Arih1 with Ube2R2 protein results in substrates modified with longer poly-
ubiquitin chains than with Arih1 alone. (a) autoradiogram of a Cyclin E ubiquitylation reaction 
with Arih1 and Ube2R2 levels sufficient to saturate the SCF complex. (b) Data points and fit to 
the kinetic model of the reaction in (a) for substrate (S0) and both mono- and di-ubiquitylated 
products (S1 and S2, respectively). Each data point represents the mean value from at least two 
independent measurements. (c,d) same as (a,b), except more with more physiological Arih1 and 




Figure 4S.9 Single-encounter Ube2R2/Arih1 reactions with βTrCP and β-Catenin. The 
combination of Arih1 with Ube2R2 protein results in substrates modified with longer poly-
ubiquitin chains than with Arih1 alone. (a,b) same as Figure 4S.8A, B, except with β-Catenin 





Figure 4S.10 Single-encounter Ube2R2/Ube2D3 reactions with Fbw7 and Cyclin E. The 
combination of Ube2D3 with Ube2R2 protein results in substrates modified with longer poly-
ubiquitin chains than with Ube2D3 alone, especially for Cyclin E peptide substrate. (a) 
autoradiogram of a Cyclin E ubiquitylation reaction with Ube2D3 and Ube2R2 levels sufficient 
to saturate the SCF complex. (b) Data points and fit to the kinetic model of the reaction in (a) for 
substrate (S0) and both mono- and di-ubiquitylated products (S1 and S2, respectively). Each data 
point represents the mean value from at least two independent measurements. (c,d) same as (a,b), 




Figure 4S.11 Single-encounter Ube2R2/Ube2D3 reactions with βTrCP and β-Catenin. The 
combination of Ube2D3 with Ube2R2 protein results in substrates modified with longer poly-
ubiquitin chains than with Ube2D3 alone, especially for Cyclin E peptide substrate. (a,b) same as 
Figure 4S.10A, B, except with β-Catenin peptide substrate and SCFβTrCP. (c,d) same as (a,b), 




Figure 4S.12 Quantified dilution series of CRL partner activities at cellular concentrations. 
Modest changes to Arih1, Ube2D3, and/or Ube2R2 levels results in substantial changes to both 
the fraction of substrate converted to products as well as the number of ubiquitins on average in a 
poly-ubiquitin chain. (a) quantitation of the fractions of substrate (S0) and all products from the 
single-encounter reactions in Figure 3 containing varying amounts of Arih1 protein. The mid-
range level was derived from Table S2. (b) same as in (a), except with Ube2D3. (c) same as in 
(a), except with Ube2R2. (d) same as in (a), except with both Arih1 and Ube2R2. (e) same as in 




Figure 4S.13 Real-time PCR of Ube2R1 mRNA after siRNA reduction of Ube2R2 mRNA. Real-
time PCR demonstrates that siRNA mediated reduction of UBE2R2 mRNA does not 
significantly affect Ube2R1 mRNA levels. (a) relative expression ratio comparing WT  293T-
FiTx or Ube2R1 knock out cells and Ube2R1 or Ube2R2 mRNA levels. (b) relative expression 
ratio for either wild-type (WT) HEK  293T-FiTx or Ube2R1 knock out cells treated with either 





Figure 4S.14 Ablation of Ube2R1/2 has no significant effect on cell cycle progression. (a) Flow 
cytometry of wild-type (WT) HEK 293T-FiTx cells that had been treated with non-targeting 
siRNA. (b) same as in (a), except with siRNA targeting UBE2R2 mRNA. (c) Flow cytometry of 
UBE2R1 knockout HEK 293T-FiTx cells that had been treated with non-targeting siRNA. (d) 
same as in (c), except with siRNA targeting UBE2R2. (e) relative expression ratio for UBE2R2 
mRNA comparing cells transfected with non-targeting siRNA (a and c) or with UBE2R2 
targeting siRNA (b and d). (f) graph showing the percentages of cells from (a-d) in various 




Figure 4S.15 Degradation of p27 unaffected by deletion of UBE2R1/2 in HEK 293T cells. (a) 
Western blot of various cell lines demonstrating the specificities of the antibodies used to detect 
Ube2R1 and Ube2R2 protein during clonal analysis. (b) Cycloheximide chase comparing p27 
levels in WT and UBE2R1/2 knockout cells. The image is representative of results from 







Figure 4S.16 Control, UBE2R1 and UBE2R2 loci used in genome-wide CRISPR screens. 
NALM-6 populations treated with sgRNAs that target AAVS1, GFP, UBE2R1 and/or UBE2R2 
as indicated. UBE2R1 and UBE2R2 protein were detected by immunoblot with anti-UBE2R1 or 
anti-UBE2R2 antibody at 1:1000 dilution. Note that since CRISPR-mediated knockout 







Figure 4S.17 Proliferation defect of UBE2R1/R2/G1 triple knockout NALM-6 cells. (a) Loss of 
UBE2R1 and UBE2R2 protein in clonal knockout NALM-6 cell lines for the UBE2R1 locus 
(top) or UBE2R2 locus (middle) or both loci (bottom). Clones used for analysis in panel b and c 
are indicated by red boxes. (b) Loss of UBE2G1 protein in AAVS1/GFP control and 
UBE2R1/UBE2R2 double knockout NALM-6 cell lines populations treated with indicated 
lentiviral constructs that target either control AZ-Green or UBE2G1. (c) Viability of colonies for 
the indicated combinations of UBE2R1, UBE2R2 and UBE2G1 knockouts. All cell lines and 
populations for validation experiments were generated in the NALM-6 doxycycline-inducible 




Figure 4S.18 UBE2G1 displays robust activity with monoubiquitylated peptide substrates. (a) 
Single encounter ubiquitylation reactions containing either saturating UBE2R2 or UBE2G1 and 
mono-ubiquitylated β- Catenin peptide substrate and SCFβTrCP or mono-ubiquitylated Cyclin E 
peptide substrate and SCFFBW7. Reactions were quenched at 10 seconds. (b) multi-turnover 
ubiquitylation reactions were assembled in the presence of constant amounts of SCFFBW7 and 
32P-labeled Ub-Cyclin E peptide and increasing amounts of UBE2G1 protein. (c) The reactions 
in (b) were plotted as a function of the UBE2G1 concentration and fit to the Michaelis-Menten 
equation using nonlinear curve fitting (Prism 6). Each data point represents the mean of the 
reaction velocities measured at least in duplicate. (d) Data points and fit to the kinetic model of 
the reaction in Figure 4.7c for mono-ubiquitylated substrate (S1) and two products (S2 and S3). 




Figure 4S.19 UBE2R1 protein is localized throughout 293T-FiTx cells. (a) Immunofluorescence 
staining of UBE2R1 protein (green; middle panel). UBE2R1 protein is visible with modest 
evident nuclear enrichment, to a lesser extent in the cytoplasm, and in adjacent pairs of foci. 
Scale bar, 5 μM. (b) Immunofluorescence staining for UBE2R1 protein (green; middle panel) 
with the HEK 293T-FiTx UBE2R1 knockout cell line. Notice that no UBE2R1 staining is 
observed. Scale bar, 20 μM. (c) Products from PCR reactions spanning the UBE2R1 exon 2 
guide RNA site were resolved by agarose gel electrophoresis. Incorporation of the oligo DNA 
into the genome should increase the PCR product by 50 base pairs. Notice that upward shifts 
were observed for multiple clones, such as 9 and 32. (d) Comparison of the specificities of both 
anti-UBE2R1 and anti-UBE2R2 antibodies, used in Figure 4 and Figure 6, against recombinant 
protein expressed in bacteria. 
142 
 
UBE2R2 Ubiquitin kobs (hr-1) Fold Loss 
WT WT 1.56 ± 0.03 - 
WT R54D 0.03 ± 0.00 52 
D143K WT 0.21 ± 0.01 7 
D143K R54D 0.36 ± 0.01 4 
WT I44A 0.58 ± 0.04 3 
WT I44R 0.79 ± 0.04 2 
D91K WT 1.64 ± 0.04 1 
D91K R54D 0.04 ± 0.01 44 
WT D58R 0.02 ± 0.00 65 
D143K D58R not detectable - 














E2 Rbx1 KM (μM) 
WT Cdc34 WT 0.15 ± 0.03 
WT Cdc34 R91E 5.40 ± 0.40 
WT UbcH5c WT 0.33 ± 0.06 
WT UbcH5c R91E 0.84 ± 0.12 
D102K Cdc34 WT 0.49 ± 0.05 
D102K Cdc34 R91E 1.83 ± 0.27 
D103K Cdc34 WT 0.22 ± 0.04 
D103K Cdc34 R91E 5.79 ± 0.83 
















 293T-FiTx 293T/17 HeLa MRC5 
ARIH1 200 ± 10 148 ± 7 200 ± 10 160 ± 10 
UBE2D1-4 2100 ± 100 1700 ± 100 1875 ± 7 1770 ± 40 
UBE2R1 70 ± 3 134 ± 3 83 ± 2 82 ± 2 
UBE2R2 132 ± 7 99 ± 6 280 ± 30 117 ± 1 
CUL1 300 ± 20 340 ± 10 134 ± 5 176 ± 1 
SKP1 2300 ± 100 1173 ± 9 1860 ± 20 1440 ± 40 
























Substrate CRL partner E3 KM (nM) kcat (min-1) 
Cyclin E ARIH1 SCFFbw7 149 ± 36 0.29 ± 0.02 
β-Catenin ARIH1 SCFβTRCP 516 ± 284 0.58 ± 0.1 
Cyclin E UBE2D3 SCFFbw7 1673 ± 460 0.77 ± 0.06 
β-Catenin UBE2D3 SCFβTRCP 488 ± 53 1.9 ± 0.04 
Cyclin E UBE2R2 SCFFbw7 not determined not determined 
β-Catenin UBE2R2 SCFβTRCP 1900 ± 100 not determined 
Ub-Cyclin E UBE2R2 SCFFbw7 317 ± 44 3.7 ± 0.1 
Ub-β-Catenin UBE2R2 SCFβTRCP 292 ± 35 3.2 ± 0.1 
Ub-Cyclin E UBE2G1 SCFFbw7 1300 ± 20 2.3 ± 0.1 























Substrate CRL partner E3 S0 S1 S2 
Cyclin E ARIH1 SCFFbw7 0.5 ± 0.04 
(0.2 ± 
0.005) 
0.2 ± 0.03 
(0.1 ± 
0.01) 
0.08 ± 0.01 
(0.1 ± 
0.02) 
β-Catenin ARIH1 SCFβTRCP 0.2 ± 0.01 
(0.1 ± 
0.005) 
0.3 ± 0.07 
(0.2 ± 
0.02) 
ND (0.1 ± 
0.02) 
Cyclin E UBE2D3 SCFFbw7 0.1 ± 0.01 
(0.06 ± 
0.003) 




β-Catenin UBE2D3 SCFβTRCP 5 ± 0.6 (3 
± 0.2) 
0.2 ± 0.04 
(0.2 ± 
0.03) 
ND (0.5 ± 
0.1) 
Cyclin E UBE2R2 SCFFbw7 0.2 ± 0.02 
(ND) 
40 ± 4 
(ND) 
4 ± 0.5 
(ND) 
β-Catenin UBE2R2 SCFβTRCP 0.1 ± 0.01 
(ND) 
30 ± 3 
(ND) 
7 ± 0.5 
(ND) 
Cyclin E ARIH/UBE2R2 SCFFbw7 0.2 ± 0.06 
(0.2 ± 
0.006) 
3 ± 2 (0.4 
± 0.03) 
4 ± 2 (1 ± 
0.1) 
β-Catenin ARIH/UBE2R2 SCFβTRCP 0.3 ± 0.05 
(0.07 ± 
0.006) 
2 ± 0.6 (0.6 
± 0.08) 
5 ± 0.8 (1 
± 0.1) 
Cyclin E UBE2D3/UBE2R2 SCFFbw7 0.2 ± 0.01 
(0.1 ± 
0.006) 
7 ± 1 (3 ± 
0.4) 
4 ± 0.3 (2 
± 0.1) 
β-Catenin UBE2D3/UBE2R2 SCFβTRCP 4 ± 0.5 (3 
± 0.3) 
0.9 ± 0.1 
(0.4 ± 
0.04) 




UBE2G1 SCFFbw7 ND (ND) 1.0 ± 0.1 
(ND) 
1.0 ± 0.1 
(ND) 
Table 4S.3 Individual rates of ubiquitin transfer for CRL partners, in units of sec-1. Rates of 
ubiquitin transfer under saturating concentrations outside of parenthesis, rates under cellular 
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